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ABSTRACT 
 
Understanding factors influencing medication utilization and provider prescribing behavior has 
important implications for the quality improvement and cost containment in health care. This 
dissertation seeks to shed light on the quality and efficiency of medication prescribing.  
Chapter one examines the association between Medicare Part D plan features and choice 
of generic antidepressants, antidiabetics, and statins using Medicare claims data. Low cost-
sharing for generics, large differentials in cost-sharing for generic vs. brand drugs, and tools such 
as prior authorization and step therapy are associated with higher generic drug use. Modifying 
the benefit design and utilization management of Medicare prescription drug plans might 
increase generic use, which could generate substantial savings for the Medicare program and for 
beneficiaries. 
Chapter two examines physician antipsychotic prescribing behavior in a large Medicaid 
program. By linking multiple data sources and using the multiple membership modeling 
approach, we examine the degree to which psychiatrists are diversified vs. concentrated in their 
choice of antipsychotic medication and identify factors associated with the concentration of 
prescribing. Antipsychotic prescribing behavior is relatively concentrated and varies 
substantially across psychiatrists regularly prescribing antipsychotics. Several characteristics of 
the treated patient population and physicians are significantly associated with antipsychotic 
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prescribing. The few characteristics of organizations examined have little influence over 
psychiatrist prescribing behavior.  
Chapter three assesses provider-level clozapine and antipsychotic polypharmacy practices 
– one with strong evidence base and the other with little support. Using multiple years’ claims 
data in a large Medicaid program, we find provider-level underuse of clozapine and use of non-
evidence supported practice of non-clozapine antipsychotic polypharmacy. However, these 
prescribing practices vary tremendously across providers. In particular, a sizable portion of 
providers use more antipsychotic polypharmacy than clozapine to their patients. Quality 
initiatives may take actions to improve evidence-based practice and to decrease unsupported 
practices in the management of antipsychotic drug use. 
This dissertation has important implications for public health because appropriate 
prescribing can alleviate tremendous health and economic burdens while inappropriate 
prescribing can generate substantial costs and increase risk of undesirable consequences. 
Understanding how providers make prescribing decisions points to potential opportunities for 
improving the quality of care and reducing cost through altering providers’ prescribing behavior. 
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1.0  IMPACT OF MEDICARE PART D PLAN FEATURES ON USE OF GENERIC 
DRUGS 
Yan Tang, Walid F. Gellad, Aiju Men, Julie M. Donohue 
Published Manuscript (Medical Care 2014; 52(6): 541-548) 
 
ABSTRACT  
Background: Little is known about how Medicare Part D plan features influence choice of 
generic vs. brand drugs. 
Objectives: Examine association between Part D plan features and generic medication use. 
Methods: Data from a 2009 random sample of 1.6 million fee-for-service, Part D enrollees ≥65 
years, who were not dually eligible or receiving low-income subsidies, was used to examine the 
association between plan features (generic cost-sharing, difference in brand and generic copay, 
prior authorization, step therapy) and choice of generic antidepressants, antidiabetics, and statins. 
Logistic regression models accounting for plan-level clustering were adjusted for 
sociodemographic and health status.  
Results: Generic cost-sharing ranged from $0 to $9 for antidepressants and statins, and from $0 
to $8 for antidiabetics (across 5th-95th percentiles). Brand-generic cost-sharing differences were 
smallest for statins (5th-95th percentiles: $16-$37) and largest for antidepressants ($16-$64) 
across plans. Beneficiaries with higher generic cost-sharing had lower generic use (adjusted odds 
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ratio [OR] = 0.97, 95% confidence interval [CI] =0.95-0.98 for antidepressants; OR = 0.97, CI 
=0.96-0.98 for antidiabetics; OR = 0.94, CI =0.92-0.95 for statins). Larger brand-generic cost-
sharing differences and prior authorization were significantly associated with greater generic use 
in all categories. Plans could increase generic use by 5-12 percentage points by reducing generic 
cost-sharing from the 75th ($7) to 25th percentiles ($4-$5), increasing brand-generic cost-sharing 
differences from the 25th ($25-$26) to 75th ($32-$33) percentiles and using prior authorization 
and step therapy. 
Conclusions: Cost-sharing features and utilization management tools were significantly 
associated with generic use in three commonly-used medication categories. 
 
Key Words: Medicare Part D, cost-sharing, prior authorization, step therapy, generic drugs 
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 INTRODUCTION 1.1
Increasing generic drug use has the potential to reduce prescription drug costs without harming 
quality, because generic equivalents are typically as effective as their brand counterparts1,2 and 
are available at a quarter of the cost.3 In fact, aggressive generic substitution has been a key 
driver of the lower than expected growth in prescription drug spending in Medicare Part D.4 
However, studies point to opportunities for substantial additional savings in Medicare from 
greater therapeutic substitution (switching from a brand drug to the generic version of another 
drug in the same class).5,6 Because consumers face much lower cost-sharing for generics, 
increasing their use may reduce cost-related non-adherence,7 and lead to substantial welfare 
gains to beneficiaries.8 
Choice of generic drugs is shaped by patient characteristics9-12 and provider 
preferences.13,14 In Medicare, differences in Part D plan features may also be an important 
determinant of drug choice. In 2009, there were 1,689 Medicare Part D stand-alone prescription 
drug plans (PDP) which differed in premiums, formularies, cost-sharing, use of utilization 
management tools, and other features.15 There was 4-fold variation across Part D plans in cost-
sharing for the top ten brand drugs in 2009. For example, cost-sharing for Lipitor ranged from 
$21 to $77 across plans.16  
There is strong evidence that demand for drugs is sensitive to cost-sharing and utilization 
management tools (e.g., prior authorization).17-26 Yet, few studies have examined the association 
between Part D plan features and choice of generic vs. brand drugs. Hoadley and colleagues, 
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using 2008 Medicare data, found low or zero cost-sharing for generic statins could increase their 
use from 51% to 88% and could result in substantial savings.27 It is not clear whether these 
findings generalize to other medications. We used 2009 Medicare data to examine whether cost-
sharing for generic and brand drugs and use of utilization management tools (prior authorization 
or step therapy) were associated with choice of generic antidepressants, oral antidiabetics, and 
statins [3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors]. We focused 
on these categories because they are widely used by older adults, account for a large share of 
drug spending,28,29 and include multiple brand and generic options with different levels of 
generic penetration. We hypothesized that lower cost-sharing for generic drugs, larger cost-
sharing differences between brand and generic drugs, and use of prior authorization and step 
therapy for brand drugs would lead to greater generic use. 
 METHODS 1.2
1.2.1 Data sources 
We analyzed data from the Centers for Medicare and Medicaid Services (CMS) for a 10% 
sample of 2009 Medicare beneficiaries (N = 4,891,885) who were continuously enrolled in fee-
for-service Parts A and B and a stand-alone Part D plan (N = 1,529,825) that year. We did not 
request data on Medicare Advantage enrollees because complete medical claims are not available 
for those enrollees. The Prescription Drug Event (PDE) file contains information for each 
prescription on date of fill, National Drug Code (NDC), days supply, total cost, amount paid by 
the PDP and beneficiary (i.e., cost-sharing), benefit phase in which the claim occurred (e.g., 
 4 
initial coverage limit, coverage gap, or catastrophic phase), whether the plan required prior 
authorization/step therapy for the drug, and encrypted identifiers for the prescriber, pharmacy, 
and plan. We used the Plan Characteristics file to obtain the plan’s monthly premium, deductible, 
and whether the plan covered generics in the gap. We obtained the primary dispenser type (e.g., 
retail, mail order) from the Pharmacy Characteristics file. We obtained the specialty of the 
provider prescribing the medication from the Prescriber Characteristics file. The Medi-Span® 
database was used to determine the drug name, category, dose, brand or generic status, and 
active ingredient by NDC.30 From the Medicare Denominator file we obtained beneficiaries’ 
demographics, ZIP code, Part D dual eligible status, and low-income subsidy (LIS) status. We 
obtained information on beneficiaries’ diagnoses and health care utilization from the claims files. 
We used 2010 Census data to get ZIP code-level information on education (proportion with high 
school education) and median household income.31 
We assigned beneficiaries to one of 306 Dartmouth Atlas of Health Care hospital-referral 
regions (HRRs) based on ZIP code32 to adjust for additional regional factors that might affect. 
1.2.2 Study sample  
We excluded low-income subsidy recipients and dual eligibles who faced low or no cost-sharing 
and beneficiaries under 65 years eligible for Medicare based on disability whose drug utilization 
patterns may differ substantially from those of older adults (N = 761,070). We further excluded 
beneficiaries who switched plans during the year (N = 20,825), or were residents of US 
territories (N = 3,468). We limited analyses to individuals with at least one prescription drug 
event for antidepressants, oral antidiabetics, or statins during the year (see Table A.1 for list of 
drugs). We eliminated a small number of enrollees (<1% of users in each category) who were in 
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PDPs with low enrollment due to difficulty in estimating cost-sharing for generic and brand 
drugs.  
1.2.3 Dependent variable 
Our primary outcome was whether a beneficiary’s first prescription within a specific category in 
2009 was for a generic. Most of the study sample used only generics or only brand drugs 
throughout the year (90.7% of antidepressant users, 79.9% of antidiabetic users, and 93.8% of 
statin users). In sensitivity analyses described in the statistical analysis section we used alternate 
specifications. 
1.2.4 Key independent variables 
The main predictors of interest were calculated at the plan-level for each therapeutic category 
separately. All prescriptions were standardized to a 30-day supply (i.e., a 90-day supply equaled 
three prescriptions). First, we calculated median cost-sharing for a generic prescription in the 
plan by therapeutic category in 2009. We used only prescription drug events from the initial 
coverage phase since cost-sharing is 100% in the coverage gap and uniform across plans after 
catastrophic coverage is in effect. Median instead of mean cost-sharing was used because of the 
skewed distribution. Overall, 89% of the claims had flat copayment and 11% had coinsurance. 
Our second key independent variable was the difference between the plan’s median cost-sharing 
for a brand drug and the plan’s median cost-sharing for a generic drug in the same category. We 
did not classify brand drugs into multiple categories (e.g., preferred vs. non-preferred brand 
drugs) because plans frequently assigned more than one drug type to a tier. Thus, it was not 
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feasible to distinguish between preferred or non-preferred brands if a tier contains more than one 
type.  Finally, we included separate indicators of whether the plan required prior authorization or 
step therapy for at least one brand drug in the category.  
1.2.5 Covariates 
Covariates included other plan features (indicators of deductible, gap coverage, and premium 
level) and beneficiaries’ demographic and socioeconomic characteristics (sex, age, 
race/ethnicity, and ZIP code-level education and income). We adjusted for a number of 
indicators of health status including person-level prescription-drug Hierarchical Condition 
Category (RxHCC) scores based on patients’ claims (inpatient, outpatient, carrier, home health 
agency, and hospice claims),33 which is a measure of health status and predictive of drug 
spending and is used to adjust PDP payments.34 In addition, we included a variable for end-stage 
renal disease (ESRD) eligibility and a set of disease-specific comorbidities for each drug 
category to adjust for clinical severity (see Table 1.1). We included separate indicators for 
whether the beneficiary had at least one hospitalization or emergency department visit in the 
year. To adjust for differences in drug choice by provider specialty we included a variable 
indicating whether the beneficiary received at least one prescription from a specialist (e.g., 
geriatric psychiatry, psychiatry, advanced practice psychiatric nurses for antidepressant users; 
endocrinology for antidiabetic users; cardiology for statins). HRR indicator variables were added 
to address additional regional factors affecting use of generic vs. brand drugs.35 
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1.2.6 Statistical analysis  
We used logistic regression models with robust standard errors clustered at the plan-level to 
estimate the association between plan features and whether a beneficiary’s first prescription was 
for a generic drug. Regressions were performed at the person-level, adjusting for all covariates 
discussed above. Correlations among plan features were tested using variance inflation factor 
(VIF) diagnostics.36 All VIFs were smaller than 2.7 indicating that the plan features were not too 
highly correlated to be included in the models. 
We conducted sensitivity analyses altering the specification of the dependent variable, 
and the analytic sample. First, we used the last prescription filled in the year instead of the first 
as the dependent variable for generic use, an outcome variable used in previous studies.27 
Second, we conducted an analysis restricting the sample to beneficiaries who did not switch 
drugs between generic and brand medications throughout the year. Third, multiple concurrent 
medication use is common among antidepressant (13.1%) and antidiabetic (36.0%) users. 
Therefore, we conducted an analysis in which the dependent variable was ‘generic drug use 
only’ in the category. The results for all of these analyses were similar to the main analysis and 
thus are not reported. We considered a sensitivity analysis for one of our key independent 
variables where instead of the difference in brand vs. generic cost-sharing in the category, we 
used the ratio; however, the ratio of brand to generic was too highly correlated with cost-sharing 
for generic drugs to be included in the same model. 
To ease interpretation of the findings, we calculated marginal effects of plan features on 
the use of generic drugs for 16 hypothetical scenarios with different plan features for each drug 
category, adjusting for all other covariates. To predict rates of generic use, we chose different 
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combinations of the 25th and 75th percentiles of the cost-sharing for generic drugs, the 25th and 
75th percentiles of the brand-generic cost-sharing differential, and whether or not prior 
authorization or step therapy was used for brand drugs.  
Analyses were performed using SAS (Version 9.3, SAS Institute, Cary, NC) and STATA 
(Version 12.0, Stata Corporation, College Station, TX). The study was deemed exempt from 
Human Subject Review by our Institutional Review Board. 
 RESULTS 1.3
1.3.1 Sample characteristics and plan features 
Our study sample included 142,767 beneficiaries using antidepressants, 101,841 using 
antidiabetics, and 318,934 using statins in 2009 (Table 1.1). More than one-quarter (27.5%) of 
the antidepressant users had at least one hospitalization as did 22.1% of antidiabetic and 19.7% 
of statin users.  
The mean absolute cost-sharing for generics was similar across the three therapeutic 
categories [$6 for antidepressants (5th-95th percentiles: $0-$9), $5 for antidiabetics (5th-95th 
percentiles: $0-$8), and $6 for statins (5th-95th percentiles: $0-$9)] (Table 1.2). Mean cost-
sharing differences between brand and generic drugs were also similar across the three drug 
categories ($32 for antidepressants, $31 for antidiabetics, $28 for statins) but varied substantially 
across plans (5th-95th percentiles: $16-$64 for antidepressants, $16-$49 for antidiabetics, and 
$16-$37 for statins).  
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Table 1.1: Characteristics of the study sample* 
 
Characteristic Antidepressants 
(N=142,767) 
Antidiabetics 
(N=101,841) 
Statins 
(N=318,934) 
Demographic and socioeconomic characteristics    
 Mean age (SD)  76.6 (7.9) 75.4 (7.0) 75.6 (7.1) 
 Female sex (%) 73.8 53.7 58.4 
 White race (%) 97.0 91.8 94.9 
 Proportion of population in ZIP code who are high 
school graduate or higher (%) 
87.3 (7.9) 86.1 (8.3) 87.3 (8.0) 
 Median household income in $ (SD) † 57,298 
(22,974) 
55,067 (21,546) 58,115 
(23,581) 
Health services utilization in 2009    
 At least one hospitalization (%) 27.5 22.1 19.7 
 At least one emergency department visit (%) 38.4 30.2 27.7 
 At least one prescription by mail order (%) 10.0 13.1 14.7 
 At least one specialist visit (%) 7.6 6.7 14.7 
Health status    
 RxHCC score (SD)‡ 1.13 (0.42) 1.17 (0.35) 1.02 (0.35) 
 End-stage renal disease (ESRD) (%) 0.55 0.52 0.48 
Disease-specific comorbidities    
 Delirium, dementia, and amnestic and other cognitive 
disorders (%) 
17.2   
 Anxiety disorders (%) 20.2   
 Bipolar disorders (%) 2.9   
 Depressive disorders (%) 38.0   
 Schizophrenia and other psychotic disorders (%) 5.0   
 Diabetic neuropathy (%)  15.0  
 Diabetic nephropathy (%)  5.8  
 Diabetic retinopathy (%)  15.4  
 Diabetes with peripheral vascular disease (%)  8.4  
 Insulin use during the year (%)  15.0  
 Hyperlipidemia (%)  84.2 92.2 
 Type 2 diabetes (%)  97.4 34.6 
 Coronary heart disease (%)   39.9 
  Stroke/TIA (%)     8.3 
Medication use in the year (%)    
 Only generic drugs 73.4 70.4 58.7 
 Only brand drugs 17.3 9.5 35.1 
 Both generic and brand drugs 9.3 20.1 6.2 
* Figures with parentheses are means and SDs. 
† Household income is based on the median income of the patient's geographic area according to ZIP 
code and 2010 U.S. Census data. 
‡ Prescription-drug Hierarchical Condition Category (RxHCC) scores are based on diagnoses from 2009 
inpatient, outpatient, carrier, hospice, and home health agencies claims and are normalized to equal 1.00 
on average for all Medicare Part D enrollees, with a range in the study sample of 0.37 to 5.90. Higher 
scores indicate an increase likelihood of higher drug spending and poorer health status. 
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Table 1.2: Plan features for the study sample* 
 
Variables   Antidepressants  Antidiabetics  Statins 
Cost-sharing for a generic drug ($) 
   
 
5th percentile 0 0 0 
 
25th percentile 5 4 5 
 
Mean 6 5 6 
 Median 7 7 7 
 
75th percentile 7 7 7 
 
95th percentile 9 8 9 
Cost-sharing difference between brand and generic 
drugs ($) 
   
 
5th percentile 16 16 16 
 
25th percentile 26 26 25 
 
Mean 32 31 28 
 Median 31 31 31 
 
75th percentile 33 33 32 
 
95th percentile 64 49 37 
Prior authorization (%) 
 
6.2 41.9 6.7 
Step therapy (%) 44.8 53.2 40.1 
Deductible (%)† 
 
21.5 21.8 21.5 
Gap coverage (%)‡ 
 
17.2 17.6 14.6 
Premium per month ($) 
    
 
5th percentile 24 24 24 
 
25th percentile 33 33 35 
 
Mean 43 43 42 
 Median 38 38 38 
 
75th percentile 44 45 43 
  95th percentile 81 81 78 
* Plan features are described at person level. 
† In Medicare Part D program, the deductible is a specific amount of money that beneficiaries have to pay 
for their prescriptions before their Part D plans start to pay their share of enrollees’ prescription drug 
claims. The deductible varies across plans, some plans may have a deductible while others do not; 
besides, plans can have different amounts for their deductibles. 
‡ The Medicare Part D standard benefit design requires beneficiaries (except those with low-income-
subsidies) to pay for 100% of total prescription costs after their expenditures exceed the initial coverage 
phase and before reaching the catastrophic coverage limit. This benefit phase is usually called “coverage 
gap” or “doughnut hole”. However, plans can offer alternative benefit designs with gap coverage that 
covers some drug costs in the gap. 
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The proportion of beneficiaries in plans requiring prior authorization varied across the 
categories, with 41.9% in plans using prior authorization for at least one antidiabetic agent vs. 
only 6.2% in plans requiring prior authorization for antidepressants and 6.7% for statins. A large 
proportion of beneficiaries were in plans with step therapy requirements (53.2% for antidiabetics, 
44.8% for antidepressants, and 40.1% for statins). More than one fifth of beneficiaries enrolled in 
plans with a deductible. The proportion of users enrolled in plans with any gap coverage was 
17.2% for antidepressants and 17.6% for antidiabetics vs. 14.6% for statins. The monthly 
premium varied substantially across plans (5th-95th percentiles: $24-$81 for antidepressant users 
and antidiabetic users, $24-$78 for statin users). 
1.3.2 Effects of plan features  
Effects of Part D plan features on generic use were similar across the three drug categories in 
2009 (Table 1.3). After adjustment for demographic, socioeconomic, and health status and 
comorbidities, beneficiaries in plans with higher average generic cost-sharing were less likely to 
use generics than those in plans with lower cost-sharing for antidepressants (odds ratio [OR] per 
$1 increase= 0.97, 95% confidence interval [CI] = 0.95-0.98, p<0.05), antidiabetics (OR = 0.97, 
CI = 0.96-0.98, p<0.05), and statins (OR = 0.94, CI = 0.92-0.95, p<0.05). Beneficiaries in plans 
with larger within-category cost-sharing differences between brand and generic drugs were more 
likely to use generic drugs than those in plans with smaller differences (antidepressants: OR per 
$1 increase= 1.01, CI = 1.01-1.02; antidiabetics: OR = 1.01, CI = 1.01-1.02; statins: OR = 1.02, 
CI = 1.01-1.02; p<0.05 for all). Enrollees in plans with use of prior authorization had 
significantly higher odds of using generics for antidepressants (OR = 1.29, CI = 1.15-1.44, 
p<0.05), antidiabetics (OR = 1.14, CI = 1.09-1.20, p<0.05), and statins (OR = 1.12, CI = 1.00-
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1.27, p<0.05) compared to their counterparts in plans without prior authorization requirement. 
Beneficiaries in plans using step therapy were more likely to use generic antidepressants (OR = 
1.07, CI = 1.02-1.13, p<0.05) and generic statins (OR = 1.13, CI = 1.08 – 1.19, p<0.05), but 
these policies were not significantly associated with use of generic antidiabetics (OR = 1.04, CI 
= 0.99 – 1.09, p = 0.15). 
Other plan features also had a significant impact on the use of generic drugs (Table 1.3). 
Beneficiaries in plans with no deductible were more likely to use generics than those in plans 
with deductibles across all three categories. Beneficiaries in plans that covered some drugs in the 
coverage gap had increased odds of using generic statins (OR = 1.24, CI = 1.04-1.47, p<0.05), 
but were no more likely to use generic antidepressants (OR = 1.09, CI = 0.90-1.30, p=0.38) or 
antidiabetic drugs (OR = 1.03, CI = 0.86-1.24, p = 0.74). Beneficiaries enrolled in plans with 
higher premiums using antidepressants or statins were less likely to use generics than those in 
plans with lower premiums, possibly because beneficiaries able to pay premiums at $50+/month 
might be less sensitive to out-of-pocket spending. However, plan premium was not associated 
with generic vs. brand use for antidiabetics.   
1.3.3 Prediction of generic use associated with plan features  
Table 1.4 shows the predicted rates of generic use in the three studied drug categories in several 
hypothetical Part D plans that vary by the key features of interest (cost sharing and utilization 
management tools). Plans could potentially increase generic use from 75.3% to 83.3% for 
antidepressants, from 79.0% to 84.2% for antidiabetics, and from 55.9% to 67.4% for statin 
drugs by reducing generic cost-sharing from the 75th ($7) to 25th percentiles ($4-$5), increasing 
brand-generic cost-sharing differences from the 25th ($25-$26) to 75th ($32-$33) percentiles and 
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using prior authorization and step therapy requirements. (Table A.2 contains predictions for all 
hypothetical plans). 
Table 1.3: Estimated effects of plan features on the use of generic drugs* 
 
Variables Adjusted Odds Ratios (95% CI) 
Antidepressants Antidiabetics Statins 
Plan cost-sharing features      
 Cost-sharing for a generic drug ($) 0.97 (0.95-0.98)† 0.97 (0.96-0.98)† 0.94 (0.92-0.95)† 
 Cost-sharing difference between brand and 
generic drugs ($) 
1.01 (1.01-1.02)† 1.01 (1.01-1.02)† 1.02 (1.01-1.02)† 
Utilization management tools    
 Prior authorization (ref=no)    
  Yes 1.29 (1.15-1.44)† 1.14 (1.09-1.20)† 1.12 (1.00-1.27)† 
 Step therapy (ref=no)    
  Yes 1.07 (1.02-1.13)† 1.04 (0.99-1.09) 1.13 (1.08-1.19)† 
Other plan features    
 Deductible (ref=yes)    
  No 1.10 (1.01-1.19)† 1.09 (1.01-1.19)† 1.45 (1.33-1.58)† 
 Gap coverage (ref=no)    
  Yes 1.09 (0.90-1.30) 1.03 (0.86-1.24) 1.24 (1.04-1.47)† 
 Premium ($, ref=$1-<30)    
  $30-50/month 0.90 (0.84-0.96)† 1.08 (1.00-1.17) 0.75 (0.69-0.81)† 
  $50+/month 0.79 (0.66-0.95)† 0.84 (0.69-1.02) 0.56 (0.46-0.67)† 
Demographic and socioeconomic 
characteristics 
   
 Sex (ref=male)    
  Female 0.94 (0.91-0.97)† 1.14 (1.10-1.18)† 1.08 (1.06-1.10)† 
 Race/ethnicity (ref=other)    
  Non-Hispanic white 0.81 (0.75-0.88)† 1.00 (0.94-1.06) 0.95 (0.91-0.98)† 
 Age group (year, ref=65-74)    
  75-84 1.05 (1.02-1.09)† 0.99 (0.95-1.03) 1.01 (1.00-1.03) 
  85+ 1.04 (1.00-1.09)† 0.94 (0.89-1.00) 1.10 (1.07-1.13)† 
 Education (%, ref=other)    
  High school graduate or higher 0.99 (0.99-0.99)† 1.00 (0.99-1.00)† 1 .00(0.99-1.00)† 
 Median household income ($) 1.00 (1.00-1.00)† 1.00 (1.00-1.00)† 1.00 (1.00-1.00)† 
Health services utilization    
 At least one hospitalization (ref=no)    
  Yes 1.06 (1.02-1.10)† 1.04 (0.99-1.09) 1.09 (1.07-1.12)† 
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Table 1.3 (Continued)    
Variables Adjusted Odds Ratios (95% CI) 
Antidepressants Antidiabetics Statins 
 At least one emergency department visit 
(ref=no) 
   
  Yes 1.02 (0.99-1.06) 1.03 (0.98-1.07) 1.05 (1.03-1.07)† 
 At least one prescription by mail order 
(ref=no) 
   
  Yes 1.15 (1.08-1.22)† 0.94 (0.88-1.01) 1.15 (1.07-1.24)† 
 At least one prescription by specialist 
prescribers (ref=no) 
   
  Yes 0.81 (0.76-0.85)† 0.60 (0.57-0.64)† 0.82 (0.81-0.84)† 
Health status    
 RxHCC score 0.89 (0.86-0.93)† 1.05 (1.00-1.11) 1.27 (1.23-1.31)† 
 ESRD (ref=no)    
  Yes 1.19 (0.98-1.43) 0.65 (0.54-0.79)† 0.99 (0.88-1.10) 
Disease-specific comorbidities    
 Antidepression specific predictors    
 Delirium, dementia, and amnestic and 
other cognitive disorders  (ref=no) 
   
  Yes 0.88 (0.85-0.91)†   
    Anxiety disorders  (ref=no)    
  Yes 1.00 (0.96-1.03)   
    Bipolar disorders  (ref=no)    
  Yes 0.97 (0.90-1.04)   
    Depressive disorders  (ref=no)    
  Yes 0.72 (0.70-0.74)†   
 Schizophrenia and other psychotic 
disorders  (ref=no) 
   
  Yes 1.07 (1.01-1.13)†   
 Antidiabetes specific predictors    
    Diabetic neuropathy  (ref=no)    
  Yes  0.96 (0.92-1.01)  
    Diabetic nephropathy  (ref=no)    
  Yes  0.76 (0.71-0.81)†  
    Diabetic retinopathy  (ref=no)    
  Yes  0.83 (0.79-0.86)†  
    Diabetes with peripheral vascular 
disease  (ref=no) 
   
  Yes  0.99 (0.93-1.05)  
    Insulin use during the year  (ref=no)   
  Yes  0.85 (0.81-0.89)†  
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Table 1.3 (Continued)    
Variables Adjusted Odds Ratios (95% CI) 
Antidepressants Antidiabetics Statins 
    Hyperlipidemia (ref=no)    
  Yes  0.89 (0.85-0.94)†  
    Type 2 diabetes (ref=no)    
  Yes  0.68 (0.61-0.77)†  
 Statins specific predictors    
    Coronary heart disease  (ref=no)   
  Yes   0.76 (0.75-0.78)† 
    Stroke/TIA  (ref=no)    
  Yes   1.03 (1.00-1.06)† 
    Hyperlipidemia (ref=no)    
  Yes   0.87 (0.84-0.90)† 
    Type 2 diabetes (ref=no)    
   Yes     1.00 (0.99-1.03) 
*Regression results were adjusted for HRR indicators. 
†Statistically significant odds ratios, p<0.05. 
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Table 1.4: Prediction of generic use* 
 
Benefit 
design 
scenario 
Cost-sharing 
for a generic 
drug ($) 
Cost-sharing 
difference ($) 
Prior 
authorization 
Step 
therapy 
Predicted 
generic use 
  
Antidepressants 
  I 7 26 N N 75.3% 
II 7 33 N N 77.1% 
III 5 26 Y Y 81.9% 
IV 5 33 Y Y 83.3% 
  
Antidiabetics 
  I 7 26 N N 79.0% 
II 7 33 N N 80.4% 
III 4 26 Y Y 83.0% 
IV 4 33 Y Y 84.2% 
  
Statins 
   I 7 25 N N 55.9% 
II 7 32 N N 58.9% 
III 5 25 Y Y 64.6% 
IV 5 32 Y Y 67.4% 
*For each drug category, we calculated marginal effects of plan features on the use of generic drugs 
(Appendix displays predicted generic use for all 16 scenarios in each drug category). We chose different 
combinations of the 25th and 75th percentiles of the cost-sharing for generic drugs, the 25th and 75th 
percentiles of the cost-sharing difference between brand and generic drugs, and whether or not prior 
authorization or step therapy was used. All covariates were adjusted for the predictions. 
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 DISCUSSION  1.4
We found that rates of generic drug use for common chronic conditions are closely related to 
Part D plan features in Medicare. Specifically, low cost-sharing for generics, large differentials 
in cost-sharing for generic vs. brand drugs, and tools such as prior authorization and step therapy 
were associated with higher generic drug use. Our analysis points to potential opportunities for 
savings5 through altering benefit design in Part D plans.  
Previous studies have reported positive associations between brand-generic cost-sharing 
differentials and use of generics in employment-based insurance.37 Our findings are similar to 
those reported by Hoadley.27 Using more recent data (2009), two additional drug categories, and 
adjusting for a richer set of health and socioeconomic status measures, our study confirms the 
association between benefit design in Part D plans and use of generic drugs. It is notable that our 
findings were quite consistent across the three drug categories in spite of differences in the 
formulary requirements for these categories, the potential for within-category polypharmacy, and 
differing generic availability. Specifically, when the Part D program was established in 2006, 
antidepressants were designated as a “protected class” requiring Part D plan formularies to cover 
all or substantially all drugs in the category38 to ensure access, although CMS is considering 
eliminating protected status for antidepressants.39 While antidepressants have similar 
comparative effectiveness, on average, these agents are not equally effective at the individual-
level and patients with depression may try multiple antidepressants before finding one that 
works.40,41 As a result, physicians may be reluctant to engage in therapeutic substitution in this 
category. It is possible that beneficiaries with poorly controlled diabetes would be prescribed 
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multiple oral antidiabetic agents, some of which have no generic equivalents. If choice of plan is 
correlated with diabetes severity our estimates of the effect of plan features may be biased. We 
addressed this issue by adjusting for a rich set of diabetes severity indicators (including several 
complications, overall comorbidity, and receiving antidiabetic prescriptions from an 
endocrinologist). Finally, while the overall rate of generic drug use was slightly lower in the 
statin class due to fewer available generic equivalents during our study period, the magnitude of 
the effects of our key plan features was similar to the other two categories.  
The Medicare Prescription Drug and Modernization Act (MMA) created a market for 
prescription drug coverage that was meant to provide multiple plan choices to beneficiaries so 
they could find a plan that best met their needs. Our findings point to relatively small variation in 
some plan features (e.g., plans’ cost-sharing for generic antidepressants ranged only from $5 to 
$7 in the 25th and 75th percentiles, respectively) and more variation in others (e.g., the cost-
sharing difference between brand and generic drugs ranged from $26 to $33 for antidepressants 
in the 25th and 75th percentiles). It is possible that our findings on the relationship between plan 
features and generic use could be partly due to selection bias if beneficiaries who are more likely 
to use generics chose plans with lower generic cost-sharing. However, the evidence on factors 
driving plan choice points to this bias being minimal. Research suggests that Part D plan choice 
is driven largely by plan premiums and that beneficiaries actually fail to pay sufficient attention 
to cost-sharing and utilization management tools when selecting plans.42,43 The typical 
beneficiary, who faces a choice of 40 plans on average, seldom chooses the optimal plan (i.e., the 
one with the lowest out-of-pocket spending for someone with their drug utilization).43,44 
Furthermore, beneficiaries are reluctant to switch plans in response to changes in their 
medication needs or plan options over time.45,46 We are, therefore, reasonably confident that 
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potential selection bias should be minimal after adjusting for the many plan- and beneficiary-
level covariates in our analyses.  
It is possible that some standardization of pharmacy benefit designs under Part D (e.g., 
requiring all plans to have very low cost-sharing for generics) may save money for the Medicare 
program and beneficiaries. However, Medicare policy has consistently favored a more market-
based approach to plan benefit design. Alternatively, CMS could add efficiency measures to its 
performance measurement for Part D plans: the Star Rating system, information available to 
consumers on the Medicare Drug Plan Finder website and used by CMS to terminate contracts 
with poorly performing Part D plans. The Star Rating system, which has been found to be 
associated with beneficiaries’ enrollment decisions,47 has 4 domains for quality measurement: 1) 
drug plan customer service; 2) member complaints, problems getting services, and improvement 
in the drug plan’s performance; 3) member experience with the drug plan; and 4) patient safety 
and accuracy of drug pricing.48 The rating system does not currently evaluate generic vs. brand 
drug use, which could be a potential measure of efficiency.  If Part D plans are rewarded for 
more generic use, they might change their cost-sharing to drive greater use of generic drugs by 
their enrollees.  
Our study has important limitations. First, while we adjusted for patients’ socio-
demographic characteristics and health status, provider-level factors, which also influence 
prescribing decisions,49 were limited to specialty of the prescriber. Second, we restricted the 
sample to those with 12 months continuous enrollment whose medication use patterns may differ 
from other Medicare beneficiaries. Third, we measured plan’s utilization management for at least 
one brand drug in the drug category using the PDE file. If no enrollees in a particular plan filled 
the drug requiring prior authorization or step therapy by the plan we would not observe the 
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utilization management requirement for that drug and may thus underestimate use of and effects 
of these tools. Fourth, use of specific utilization management tools (e.g., prior authorization) vary 
from year to year so our findings may not generalize to other years. Fifth, it is difficult to predict 
beneficiaries’ behavioral responses in drug categories where polypharmacy is common (e.g., 
antidiabetics). If beneficiaries respond to reductions in generic drug copays by combining a 
generic with a brand drug to treat the same condition instead of substituting the generic for the 
brand, changes in cost-sharing features may not result in savings. Finally, if beneficiaries 
purchased generic drugs at discounted prices without using the plan (e.g., $4 generic programs), 
use of generic drugs would be underestimated. Since use of these programs was relatively 
limited among elderly beneficiaries at the time,50 their impact on our findings should be minimal. 
In conclusion, lower cost-sharing for generic drugs, larger brand-generic cost-sharing 
differences, and use of prior authorization and step therapy requirements were associated with 
greater use of generic drugs in three widely used drug categories in Part D. Modifying the benefit 
design and utilization management of Medicare prescription drug plans might increase generic 
use, which could generate substantial savings for the Medicare program and for beneficiaries. 
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2.0  PATIENT, PHYSICIAN AND ORGANIZATIONAL INFLUENCES ON THE 
CONCENTRATION OF ANTIPSYCHOTIC PRESCRIBING IN MEDICAID 
Yan Tang, Chung-Chou H. Chang, Judith R. Lave, Walid F. Gellad, Haiden A. Huskamp, 
Julie M. Donohue 
 
ABSTRACT 
Objectives: Antipsychotics have been approved to treat several serious mental disorders. Given 
considerable variability in treatment response and medication side effects across individual 
patients using antipsychotic drugs, customizing treatment to the needs of each individual is key 
to improving patient outcomes. This study examined the degree to which psychiatrists were 
diversified vs. concentrated in their choice of antipsychotic medication and identified patient, 
physician, and organization-level factors associated with the concentration of antipsychotic 
prescribing. 
Methods: Using 2011 data from Pennsylvania’s Medicaid program we identified all 
psychiatrists who regularly prescribed antipsychotics (defined as 10 or more unique patients in 
that year). Using prescriber ID we linked claims data, from which we obtained information on 
patient characteristics and psychiatrist prescribing behavior, to demographic information on 
psychiatrists from the AMA Masterfile, and to IMS Health’s HCOS TM database from which we 
obtained information on psychiatrists’ organizational affiliations. We used three measures of 
antipsychotic prescribing concentration: the number of ingredients ever prescribed in the year, 
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the share of prescriptions for the most preferred ingredient, and the Herfindahl index (HHI). We 
used descriptive analyses and multiple membership linear mixed models with restricted 
maximum likelihood estimation to evaluate the degree of physician-level concentration for 
antipsychotic prescribing. Predictors included patient characteristics (e.g., diagnoses, disability 
status, demographics), physician characteristics (e.g., sex, age, educational background, practice 
location), and features of affiliated health care organizations (e.g., inpatient vs. clinic, behavioral 
health specialty).  
Results: The analytic cohort included 764 psychiatrists treating 65,256 patients. Psychiatrists 
prescribed several unique ingredients (mean number: 9); however, prescribing behavior was 
relatively concentrated (share of most preferred ingredient: 37.8%; mean HHI: 2,603), with wide 
variation across psychiatrists in all measures (range number of ingredients: 2-17; share of most 
preferred ingredient: 16.4%-84.7%; HHI: 1,088-7,270). About 15% of psychiatrists had a HHI 
higher than 3,333, which suggests that these psychiatrists only prescribed 3 ingredients equally 
to their patients (each 33.3%), or prescribed more ingredients but relied heavily on only 1 or at 
most 2 ingredients. Having a higher share of SSI-eligible patients and patients with serious 
mental illnesses was associated with less concentrated (more diversified) prescribing although 
effects were relatively small (p<.01 or p<.05). Female psychiatrists prescribed 0.29 fewer unique 
antipsychotic ingredients than did males (p<.10) and had a HHI that was 97.5 units higher 
(p<.10). Psychiatrists affiliated with behavioral health organizations had more diversified 
antipsychotic prescribing in terms of number of ingredients (p<.10). By increasing psychiatrist’s 
share of patients with serious mental illnesses from 20% to 100%, the degree of concentration 
would decrease (e.g., from 3,102 to 2,382 for HHI). Similar patterns were also found by share of 
SSI-eligible patients. 
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Conclusions: Antipsychotic prescribing behavior in a large state Medicaid program was 
relatively concentrated and varied substantially across psychiatrists regularly prescribing 
antipsychotics. Some psychiatrists treating Medicaid enrollees with antipsychotics may be 
limited in their ability to tailor treatment to individual patient needs and preferences. 
Psychiatrists treating more disabled patients with a higher prevalence of severe mental illnesses 
had slightly more diversified prescribing although the effects were small. Health systems may 
consider exploring strategies for educating providers or guiding patients to providers with greater 
ability to tailor treatment decisions. 
 
Key Words: physician prescribing, customization, concentration, variation, antipsychotics 
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 INTRODUCTION 2.1
Physicians often face many choices when prescribing drugs in a therapeutic class. In some drug 
classes a most effective drug may exist for the treatment of certain diseases. For example, when 
treating patients with diabetes and other heart risk factors, ramipril in the drug class of 
antiotension-converting enzyme (ACE) inhibitors has been proven to be the most effective drug 
in that class to reduce the risk of heart attack, stroke, and premature deaths.51 However, in most 
drug classes there is no “best drug” for all patients; but there is “best drug” for a particular 
patient. Accordingly, appropriate prescribing is the result of a matching process that results in 
identifying the medication that best fits the patient’s clinical characteristics and preferences. 
Although personalizing prescribing choices to each individual could potentially lead to better 
clinical outcomes –sometimes by improving medication adherence, which is evidenced in 
antidepressant treatment,52,53 many physicians tend to prescribe the same drug (or only a limited 
subset of drugs) to all patients.54  
There are now more than 20 molecules and their reformulations in the class of 
antipsychotic drugs.55 As a top-selling drug class,56  antipsychotics have been approved by the 
US Food and Drug Administration (FDA) to treat several serious psychiatric conditions 
including schizophrenia, bipolar disorder, major depressive disorder, and autism. Off-label use of 
antipsychotics for other conditions is also common.57,58 The widespread substitution of atypical 
(new) for conventional (old) antipsychotics in the past two decades resulted in high expenditures 
for antipsychotics, which are mainly financed by Medicare and state Medicaid programs.59 
Although atypicals were introduced with the promise of greater effectiveness and safety than 
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their conventional counterparts, comparative effectiveness research found that non-clozapine 
atypicals are no more effective than conventional antipsychotics.60,61 Because there is 
considerable variability in treatment response and medication side effects across individual 
patients using antipsychotic drugs,62,63  tailoring treatment to the needs and preferences of 
patients is essential to achieving good clinical outcomes. In fact, a major focus of the National 
Institute of Mental Health (NIMH) in recent years has been fostering personalized medicine to 
improve health outcomes.64 
Despite a wide variety of choices in antipsychotic products, two studies have found 
antipsychotic prescribing to be relatively concentrated although they differed in their sampling 
frame and study period.55,65 These findings are similar to results reported from studies examining 
prescribing concentration in multiple disease conditions (acute vs. chronic diseases)54 and the 
drug class of antidepressants.52  The studies examining antipsychotic prescribing concentration 
adjusted for physician characteristics but did not have information on the patient case mix or on 
the setting in which the physicians practiced. In addition to physicians’ own characteristics66,67 
(e.g., education and training background, practicing experience, age), characteristics of the 
treated patient population (e.g., demographic factors, health status and clinical needs) may also 
influence prescribing decision because physician is expected to act in patient’s best interests and 
to personalize treatment as her agent.68  Furthermore, physician prescribing practices may be 
shaped by the organizations within which they practice through multiple mechanisms (e.g., 
guideline dissemination, quality improvement initiatives, normative influences, financial 
incentives).49,69 
This study examined physician antipsychotic prescribing behavior in the Medicaid 
program because of the important role Medicaid plays in financing antipsychotic drugs. Using 
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2011 Pennsylvania’s Medicaid dataset and information from IMS Health databases and the 
American Medical Association (AMA) Masterfile, we assessed psychiatrists’ prescribing of 
antipsychotics and the influence of patient characteristics, physician characteristics, and 
organizational features. 
 METHODS 2.2
2.2.1 Overview 
By linking 2011 data from Pennsylvania’s Medicaid program, AMA Masterfile, and IMS 
Health’s HCOS TM dataset, we identified psychiatrists who regularly prescribed antipsychotics 
(defined as psychiatrists who treated 10 or more unique Medicaid patients in that year). We 
constructed 3 measures to quantify the degree of concentration for psychiatrist antipsychotic 
prescribing. A number of continuous and categorical variables were constructed to describe the 
characteristics of treated patient population, physician characteristics, and features of the health 
care organizations with which psychiatrists were affiliated. Using descriptive analyses and 
multiple membership linear mixed models, we examined the degree of physician-level 
concentration for antipsychotic prescribing in this large Medicaid program and the three types of 
factors associated with psychiatrists’ prescribing behavior. 
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2.2.2 Data sources 
Medicaid data  
We obtained data on patient characteristics, physician and practice setting information for 
calendar year 2011. Pennsylvania’s Medicaid dataset from the Department of Public Welfare 
(DPW) contains enrollment information, medical claims (inpatient, outpatient, and professional), 
pharmacy claims for the 2.2 million individuals who were enrolled in either fee-for-service or 
managed care programs. It also contains a provider file for providers who bill for visits with 
Medicaid patients. This file includes prescribing provider’s information such as National 
Provider Identifier (NPI), name, and ZIP code information for practice location. From the 
enrollment file we obtained beneficiaries’ demographic information (age, sex, race/ethnicity), 
dual eligible status, eligibility type [SSI (Supplemental Security Incomes), TANF (temporary 
assistance for needy families), GA (general assistance), waiver], and insurance type (fee-for-
service vs. individual managed care programs). The eligibility type of general assistance is a 
Pennsylvania-specific program for nonelderly adults with a temporary disability, limited income 
or special circumstances. We obtained information on patients’ diagnoses using the outpatient, 
professional, and inpatient claims files. As indicated below, we used these data to describe the 
psychiatrists’ patient population. The pharmacy claims file includes prescription information 
such as the National Drug Code (NDC), date of fill, dose, form, days supply, and prescribing 
provider identifier. We used the Medi-Span® database to acquire antipsychotic drugs’ 
information including drug name, dose, and active ingredient by NDC.70 
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Physician characteristics 
Using the NPI, we linked prescribers with at least one antipsychotic prescription in 
Pennsylvania’s Medicaid database to physician characteristics from the AMA Masterfile and to 
information on organizational characteristics from the 2011 IMS Health’s Healthcare 
Organizational ServicesTM (HCOS) database. The AMA Masterfile, which includes data on all 
physicians (both domestic and foreign graduates) practicing in the US, contains information on 
physician demographic, specialty, medical education, and other information.71  
Organizational affiliation and characteristics  
We obtained information on organizational affiliation from IMS Health’s HCOSTM database, on 
all US psychiatrists with ≥10 antipsychotic prescriptions in 2011.  HCOSTM identifies physician 
affiliations with health care organizations (e.g., medical groups, hospitals, nursing homes), along 
with the type of affiliation with each organization (e.g., attending, affiliated, admitting, staff, 
consulting, treating). HCOSTM also contains information on the specialty of the organization, for 
example, whether a medical group had a primary care or behavioral health specialty, and the 
total number of providers from all specialties affiliated with that organization.72 The HCOSTM 
database seldom captures solo or 2-person practices, but includes virtually all hospitals in 
Pennsylvania according to the hospital list from the Centers for Medicare and Medicaid Services 
(CMS) Hospital Compare database,73 and larger medical groups, clinics or outpatient facilities.  
2.2.3 Study population 
We identified psychiatrists prescribing at least one antipsychotic drug to Medicaid beneficiaries 
who were under the age of 65 and not dually eligible for Medicare. We excluded dual eligible 
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beneficiaries because Medicaid data do not contain complete claims information for those 
beneficiaries, particularly for prescription drugs. We then limited our analyses to all psychiatrists 
who regularly prescribed antipsychotics to 10 or more unique Medicaid enrollees in 2011. Low 
volume prescribers provide little information about the diversity of antipsychotic prescribing and 
account for a small fraction of antipsychotic prescribing (<1% of the prescriptions by 
psychiatrists participating in Pennsylvania Medicaid were prescribed by prescribers with ≤9 
patients using antipsychotic drugs in 2011) so they were not included in the analyses (see Figure 
B.1 for physician-level concentration of antipsychotic prescribing by physician patient volume 
and Figure B.2 for the sample size flow chart). 
2.2.4 Outcome variables 
We constructed three outcome variables to capture the degree of physician-level 
concentration/diversity for antipsychotic prescribing. We considered concentrated prescribing to 
be the opposite of diverse prescribing; more concentrated antipsychotic prescribing indicates less 
diversified prescribing and vice versa. The first outcome measure was the number of unique 
ingredients ever prescribed in the year. A recent study examining adoption of second-generation 
antipsychotics implies tremendous variation in the time to adoption and sizable differences in 
number of agents prescribed across specialties.74 The second outcome measure was the share of 
prescriptions accounted by the psychiatrist’s most preferred antipsychotic ingredient, a measure 
of prescribing concentration used in previous research.54 Studies have documented that 
prescribers tended to have favorite agents when multiple drugs were available in a therapeutic 
class.52-54 The third outcome measure was Herfindahl index (HHI), which is a commonly 
accepted measure of market concentration of firms75-77 but has also been applied to measure the 
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concentration of product choice within physicians.52,53,55,65 In economic studies, if HHI is greater 
than 1,800, it reflects a highly concentrated market.78 We calculated the HHI for a psychiatrist 
who prescribed N unique antipsychotic ingredients in 2011, by summing up the square of each 
antipsychotic ingredient’s prescription share. The value of the HHI index ranged from 10,000/N 
(if a physician prescribed each of N antipsychotic ingredients with equal share) to 10,000 (if a 
psychiatrist prescribed only one antipsychotic ingredient). The HHI index incorporates 
information on both number and share of antipsychotic ingredients prescribed by the psychiatrist, 
with a larger value implying more concentrated and a smaller value indicating more diversified 
prescribing behavior.  
A larger number of ingredients indicates less concentrated (more diversified) prescribing 
of antipsychotics, while higher share of ingredients prescribed made up by the most preferred 
ingredient and a higher HHI imply a more concentrated (less diversified) prescribing behavior. 
Each of the three measures captures a slightly different aspect of concentration; the three 
variables together can comprehensively explore psychiatrists’ concentrated vs. diversified 
prescribing behavior of antipsychotic drugs. 
2.2.5 Explanatory variables 
We examined three types of predictors of antipsychotic prescribing: characteristics of the treated 
patient population, physician characteristics, and features of the health care organizations with 
which psychiatrists were affiliated.  
We used data on patient characteristics to adjust for differences in the psychiatrists’ 
caseloads. For each psychiatrist we calculated the share of his or her patients in certain 
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sociodemographic groups (share that were female, non-Hispanic white, under 18 years old, and 
50 or older). We included a variable of the share of patients eligible for Medicaid through SSI to 
measure disability status. To adjust for possible variability in management of antipsychotics by 
payers we included a variable for the share of a psychiatrist’s patients in fee-for-service vs. 
managed care programs. The only prior authorization policies in existence were for children 
under 18 years old. Furthermore, antipsychotic policies in Pennsylvania Medicaid did not target 
a particular agent. To adjust for patients’ health status and diagnosis, we included psychiatrist’s 
share of patients with serious mental illnesses [any diagnosis of schizophrenia (ICD-9 codes: 
295.xx), bipolar disorder (ICD-9 codes: 296.0, 296.1, 296.4, 296.5, 296.6, 296.7, 296.8), major 
depressive disorder (ICD-9 codes: 296.2, 296.3), or autism spectrum disorder (ICD-9 codes: 
299.xx, excluding 299.9)]. To capture patient population’s non-mental comorbidities, first, for 
each patient we constructed separate indicators of 25 non-mental illness Elixhauser comorbidity 
index (a widely used comorbidity measure)79-81 based on patient’s medical claims.  Second, we 
created a variable for physician-level share of patients with 2 or more of these conditions based 
on the distribution in our patient sample. 
The physician characteristics included psychiatrist’s sex (female vs. male), age categories 
(≤40, 40–49, 50–59, ≥60), educational background (whether the psychiatrist graduated from a 
top 20 medical school according to 2011 US News and World Report Rankings, and whether 
he/she received a degree from US or foreign medical school), prescription volume measured by 
total number of antipsychotic prescriptions in the year, and whether the psychiatrist only 
practiced in an urban area based on the ZIP code of practice settings. We measured each 
psychiatrist’s professional network by calculating the total number of other regular antipsychotic 
prescribers in all health care organizations with which the psychiatrist was affiliated. We 
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hypothesized that psychiatrists practicing in larger organizations may have more diversified 
prescribing behavior than those in smaller organizations due to greater availability of information 
from peers.  
To measure features of affiliated health care organizations, we included dummy variables 
for organizational affiliation type (whether the psychiatrist practiced in outpatient only, inpatient 
only, or in both outpatient and inpatient organizations), and an indicator of whether the 
psychiatrist was affiliated with any behavioral health organization (psychiatric hospital, or 
medical group with specialization in behavioral health/addiction medicine). We also included a 
variable of number of providers from all disciplines as a proxy for organization size. Because 
each organization with which a psychiatrist was affiliated had its own number of providers, and 
the degree of membership with different organizations for each psychiatrist varied, the new 
variable of provider numbers for each psychiatrist was derived as the weighted average of the 
provider numbers across all the organizations to which the psychiatrist belonged. Weights were 
applied based on the weighting structure of the multiple membership modeling82 as discussed in 
more detail below. 
2.2.6 Statistical analysis 
Descriptive analysis 
We examined the distribution of the 3 outcome variables across psychiatrists in the study sample, 
reporting mean, standard deviation, percentiles, and calculated the coefficient of variation, a 
commonly used measure of variability.65,83 
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Multiple membership data structure and modeling 
Traditional multilevel models are used to analyze data that have hierarchical or nested structures 
(i.e., each observation at a lower level is nested within a single unit at a higher level).84-87 
However, sometimes the assumption of purely hierarchical data structure does not hold in 
practice.88,89 One complex type of non-hierarchical data is multiple membership structure, in 
which lower-level observations are not nested within only one higher-level unit; instead, they are 
members of multiple higher-level units simultaneously.88,90 For example, a psychiatrist (lower-
level unit) may be affiliated with more than one health care organization (higher-level unit) 
during the year as is the case in our sample. In analyses with multiple membership data structure, 
it is assumed that there are known weights which could be used to quantify the degree of 
membership for a lower-level unit to the different higher-level units. The sum of weights across 
different clusters for each lower-level unit equals to 1.  
To tackle the complexity of multiple membership data structure, we used the multiple 
membership linear mixed models with restricted maximum likelihood estimation (REML) for the 
evaluation of the 3 continuous outcome measures, which were approximately normally 
distributed in the study sample. We used REML other than maximum likelihood estimation (ML) 
because REML not only provides unbiased estimates but also takes into account the loss of 
degrees of freedom due to the inclusion of covariates.91 All regressions were performed at the 
physician-level. The regression models included fixed effects for all explanatory variables 
discussed above and health care organization-level random effects. The model can be expressed 
as: 
𝑦𝑦𝑖𝑖 = 𝛽𝛽0 + 𝛽𝛽1𝑥𝑥𝑖𝑖,𝑝𝑝𝑝𝑝 + 𝛽𝛽2𝑥𝑥𝑖𝑖,𝑝𝑝ℎ𝑦𝑦 + 𝛽𝛽3𝑥𝑥𝑖𝑖,𝑜𝑜𝑜𝑜𝑜𝑜 +  𝛽𝛽4 � 𝑤𝑤𝑗𝑗,𝑖𝑖2 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑗𝑗2
𝑗𝑗∈𝑜𝑜𝑜𝑜𝑜𝑜(𝑖𝑖) + � 𝑤𝑤𝑗𝑗,𝑖𝑖2 𝜇𝜇𝑗𝑗2𝑗𝑗∈𝑜𝑜𝑜𝑜𝑜𝑜(𝑖𝑖) + 𝑠𝑠𝑖𝑖 
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where 𝑦𝑦𝑖𝑖 represents the outcome variable for psychiatrist 𝑠𝑠. 𝛽𝛽0 is the intercept. 𝑥𝑥𝑖𝑖,𝑝𝑝𝑝𝑝 is a 
vector of variables for patient characteristics for psychiatrist 𝑠𝑠, with corresponding vector of 
coefficients 𝛽𝛽1; similarly, 𝑥𝑥𝑖𝑖,𝑝𝑝ℎ𝑦𝑦 stands for a vector of variables for psychiatrist characteristics 
with coefficients 𝛽𝛽2 for psychiatrist 𝑠𝑠;  and 𝑥𝑥𝑖𝑖,𝑜𝑜𝑜𝑜𝑜𝑜 is a vector of organizational setting factors for  
psychiatrist 𝑠𝑠 with corresponding coefficients 𝛽𝛽3. 𝑤𝑤𝑗𝑗,𝑖𝑖2  measures the degree of membership for 
psychiatrist 𝑠𝑠 (level 1) to organization 𝑗𝑗 (level 2), summing to 1 for psychiatrist 𝑠𝑠.  𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑗𝑗2 
represents total number of providers for organization 𝑗𝑗 (level 2). ∑ 𝑤𝑤𝑗𝑗,𝑖𝑖2 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑗𝑗2𝑗𝑗∈𝑜𝑜𝑜𝑜𝑜𝑜(𝑖𝑖)  is the 
weighted average of the provider numbers across all the organizations (level 2) with which 
psychiatrist 𝑠𝑠 was affiliated,  𝛽𝛽4 stands for corresponding coefficient. The first 5 items on the 
right-hand side of the model are termed the fixed part of the model. ∑ 𝑤𝑤𝑗𝑗,𝑖𝑖2 𝜇𝜇𝑗𝑗2𝑗𝑗∈𝑜𝑜𝑜𝑜𝑜𝑜(𝑖𝑖)  represents 
the weighted sum of organizational-level random effect, and 𝑠𝑠𝑖𝑖 is the residual error term. The last 
2 terms stand for the random part of the equation.  
The affiliation type identifies the relationship a psychiatrist has with a health care 
organization (e.g., attending, affiliated, or admitting in a hospital; staff, consulting, or treating in 
a nursing home), which was used to construct the weighting structure to represent the extent of 
membership for a psychiatrist to each of his or her affiliated organizations. Medical group 
affiliations were given the same weight as the affiliation type “attending” in inpatient facilities. 
We categorized the degree of membership into 2 groups based on this information: 1) “strong 
relationship” if a psychiatrist was affiliated with a medical group, had an attending relationship 
with a hospital, practiced at an outpatient location of a hospital (affiliated provider), or was 
contractually on staff at a nursing home (staff); 2) “weak relationship” if a psychiatrist admitted 
patients to a hospital but was not designated as an attending or affiliated provider, consulted or 
treated patients at a nursing home without being on staff.  
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In the main analysis, we assigned the weighting ratio of “strong relationship” to “weak 
relationship” to be 5:1 (total weights summed to 1 for each psychiatrist), assuming affiliated 
organizations in the “strong relationship” group would be more influential to the psychiatrist’s 
prescribing behavior than organizations in the “weak relationship” group. To check the 
robustness of the results, in sensitivity analyses we explored other weighting schemes: 1:1 (i.e., 
equal weights), 10:1, and 2:1. 
In addition, we ran the regressions on each outcome without including any explanatory 
variable. Variation reductions between the null and above full models were reported. Finally, to 
assess the degree of concentration in response to the severity of patient illness (since prescribing 
customization is expected to meet patients’ clinical needs), we predicted the 3 outcomes on 
antipsychotic prescribing by share of patients with serious mental illnesses and by share of SSI-
eligible patients, respectively. All other covariates were adjusted for the predictions.  
SAS (Version 9.4, SAS Institute, Cary, NC) and STATA (Version 13.0, Stata 
Corporation, College Station, TX) were used for the analyses. 
 RESULTS 2.3
2.3.1 Physician and patient characteristics 
In 2011, a total of 764 psychiatrists treating 65,256 patients in the Pennsylvania Medicaid 
program were included in our sample (the median number of treated patients was 68 for a 
psychiatrist).  Of the 764 psychiatrists in the study, 33.3% were female, more than half (55.9%) 
were 50 years of age or older, 44.0% graduated from foreign schools.  At the physician-level, the 
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mean share of SSI-eligible patients was 69.6% and the mean share of patients with serious 
mental illnesses was 77.7% (Table 2.1).  
2.3.2 Organizational and physician affiliations  
Among the study sample, about half (50.5%) of the psychiatrists were affiliated with 2 or more 
organizations in 2011 (mean number of organizations per physician: 1.9; range: 1–7), 38.2% had 
an affiliation with at least one behavioral health organization (psychiatric hospital, or medical 
group with specialization in behavioral health/addiction medicine) (Table 2.1). More than half 
(57.9%) were affiliated with inpatient organizations only, 15.8% were affiliated with outpatient 
organizations only and 26.3% with both inpatient and outpatient organizations. Of the 539 
organizations with which the psychiatrists billing Pennsylvania Medicaid were affiliated, the 
majority of them (63.5%) were non-behavioral health organizations and most (63.6%) were 
inpatient organizations (Table 2.2). The mean number of regular antipsychotic prescribers 
affiliated with these organizations was 3. 
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Table 2.1: Descriptive characteristics of regular psychiatrist prescribers 
 
Characteristic   Mean (SD) or percent 
N 
 
764 
Characteristics of provider’s treated patients 
 
 
Demographic information 
 
  
Share of female patients (%) 49.59 (15.10) 
  
Share of SSI-eligible patients (%) 69.60 (13.94) 
  
Share of non-Hispanic whites (%) 62.80 (27.20) 
  
Share of patients <18 years old (%) 23.41 (31.36) 
  Share of patients ≥50 years old (%) 18.29 (15.00) 
 
Health status 
 
  
Mean number of non-mental comorbidities 1.39 (0.66) 
  
Share of patients with serious mental illnesses (%) 77.72 (16.46) 
 
Health insurance 
 
  
Share of patients enrolled in fee-for-service program (%) 22.14 (32.51) 
Physician characteristics 
 
 
Female 33.25% 
 
Physician age 
 
  
<40 15.97% 
  
40–49 28.14% 
  
50–59 33.25% 
  
≥60 22.64% 
 
Attended medical school 
 
  
US top 20 8.77% 
  
Ranked ≥21 47.25% 
  
Foreign schools 43.98% 
 
Number of antipsychotic prescriptions (#) 
 
  1st quartile (13-99) 55.82 (23.48) 
  2nd quartile (100-279) 182.09 (54.92) 
  3rd quartile (281-742) 483.72 (141.85) 
  4th quartile (746-8,234) 1,572.72 (1,057.20) 
 
Number of other antipsychotic prescribers in the same 
 
 
  
0 7.59% 
  
1–9 39.92% 
  
≥10 52.49% 
 
Practice in urban only 86.65% 
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Table 2.1 (Continued)  
Characteristic Mean (SD) or percent 
Organizational setting 
 
 
Number of affiliated organizations 
 
  1  49.48% 
  2 28.14% 
  ≥3 22.38% 
 Any affiliation with a behavioral health organization 38.22% 
 
Organizational affiliation types 
 
  
Outpatient only 15.84% 
  
Inpatient only 57.85% 
  
Both inpatient and outpatient 26.31% 
  Organization size measured by number of providers* 
 
  1st quartile (1-35) 12.20 (8.27) 
  2nd quartile (36-208) 96.79 (48.62) 
  3rd quartile (210-464) 314.79 (60.13) 
  4th quartile (466-3,392) 972.38 (603.61) 
* Number of providers includes providers of all disciplines affiliated with a business. 
 
 
Table 2.2: Features of affiliated organizations of the study sample 
 
Characteristic Number (percent) 
Total number of organizations 539 
Number stratified by organization specialty 
 
 
Behavioral health 197 (36.55%) 
 
Non-behavioral health 342 (63.45%) 
Number stratified by organization type 
 
 
Outpatient 196 (36.36%) 
 
Inpatient 343 (63.64%) 
  
Acute care hospitals 222 (41.19%) 
  
Psychiatric hospitals 36 (6.68%) 
  
Nursing homes 81 (15.03%) 
  
Rehabilitation hospitals 4 (0.74%) 
Mean number of providers of all disciplines/organization [mean (SD)]* 249.60 (464.55) 
Mean number of regular antipsychotic prescribers/organization [mean (SD)] 3.05 (5.11) 
* Number of providers includes providers of all disciplines affiliated with a business. 
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2.3.3 Variation in physicians’ antipsychotic prescribing  
Variations in unadjusted number of ingredients, share of most preferred ingredient, and HHI 
across psychiatrists are shown in Table 2.3. Psychiatrists prescribed several unique ingredients, 
an average of 9 in 2011. However, prescribing behavior was relatively concentrated. 
Psychiatrists wrote 37.8% of prescriptions for their most preferred ingredient, and the mean HHI 
was 2,603 (maximum value 10,000) -- which equals 3.9 ingredients used equally (each 25.5%), 
or ≥4 ingredients used but with a limited subset of drugs being predominantly prescribed. Of the 
764 psychiatrists, 114 (14.9%) had a HHI higher than 3,333, which suggests that these 
psychiatrists only prescribed 3 ingredients equally to their patients (each 33.3%), or prescribed 
more ingredients but relied heavily on only 1 or at most 2 ingredients.  
There was substantial variability in all three measures of concentration across 
psychiatrists, with number of ingredients ranging from 2 to 17, share of most preferred ingredient 
ranging from 16.4% to 84.7%, and HHI from 1,088 to 7,270.  The coefficient of variation was 
0.33 both for number of ingredients and for HHI, and 0.29 for share of most preferred ingredient, 
suggesting moderate to large variability in concentration.83 There were 12 antipsychotic 
ingredients on the list of most preferred antipsychotics by psychiatrists, among which quetiapine 
was preferred by 42.7% of the psychiatrists, followed by risperidone (34.0%) and aripiprazole 
(17.2%) (see Figure B.3 for the complete list of psychiatrists’ preferred antipsychotics). 
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Table 2.3: Distributions of number of ingredients, share of most preferred ingredient, and 
HHI of the study sample 
 
Variable Number of ingredients 
Share of most preferred 
ingredient (%) 
HHI of 
ingredients 
Mean (SD) 9 (3) 37.83 (11.00) 2,603 (847) 
5th percentile 4 22.73 1,530 
25th percentile 6 29.76 1,991 
50th percentile 9 36.06 2,483 
75th percentile 11 43.75 3,018 
95th percentile 14 58.41 4,073 
Range across all providers 2-17 16.38-84.74 1,088-7,270 
Ratio of 75th to 25th percentiles 1.83 1.47 1.52 
Coefficient of variation 0.33 0.29 0.33 
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2.3.4 Predictors of the concentration of physicians’ antipsychotic prescribing  
Characteristics of treated patients 
Table 2.4 reports results from the multiple membership linear mixed models. Of the 3 types of 
factors included in the regressions, several characteristics of the treated patients were associated 
with psychiatrists’ antipsychotic prescribing although the effects were relatively small. After 
adjusting for physician characteristics and organizational features, psychiatrists with a 1 percent 
increase in share of SSI-eligible patients were associated with a 0.02 unit increase in number of 
ingredients (p<.05), a 0.16 percent decrease in share of the most preferred antipsychotic 
ingredient (p<.01) and a 13.2 unit decrease in HHI (p<.01). Similarly, a 1 percent increase in 
psychiatrists’ share of patients with serious mental illnesses was associated with a 0.02 unit 
increase in number of ingredients (p<.01), a 0.11 percent decrease in share of antipsychotic 
prescriptions for most preferred ingredient (p<.01), and a 9.0 unit decrease in HHI (p<.01). 
Psychiatrists with a 1 percent increase in share of patients <18 years old were associated with a 
0.03 unit decrease in number of ingredients, a 0.07 percent increase in most preferred ingredient, 
and a 8.0 unit increase in HHI (all p<.01). Other patient characteristics, including a larger share 
of older patients (p<.05 for share of most preferred ingredient, and p<.1 for HHI) and higher 
share of non-Hispanic whites (p<.1 for both share of most preferred ingredient and HHI), were 
also significantly associated with more diversified prescribing behavior of antipsychotics. We 
predicted the marginal effects on prescribing concentration by 2 patient-level variables of interest 
(Figure 2.1). By increasing psychiatrist’s share of patients with serious mental illnesses from 
20% to 100% (using the range observed in our study sample), the degree of concentration of 
antipsychotics prescribing would decrease significantly in terms of share of most preferred 
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ingredient (from 43.4% to 34.6%) and HHI (from 3,102 to 2,382). Similar patterns were also 
found by share of SSI-eligible patients. 
Physician characteristics 
Of the several physician characteristics examined, only physician sex and prescribing volume 
were significantly associated with prescribing concentration (Table 2.4). Controlling for all other 
explanatory variables, female psychiatrists prescribed 0.29 fewer antipsychotic ingredients than 
did male psychiatrists and had a HHI that was 97.5 units higher than that of their male 
counterparts although both associations were only significant at the p<.1 level . Older physicians 
appeared to be more concentrated in their antipsychotic prescribing behavior, although this 
association was not statistically significant at the p = 0.1 level. 
Organizational setting 
In regard to the 3 organizational factors included in the regressions, only 1 variable was 
significantly associated with the degree of concentration for antipsychotic prescribing (Table 
2.4). Psychiatrists who had any affiliation with behavioral health organizations tended to 
prescribe 0.8 more unique antipsychotic ingredients compared to those who did not have 
affiliation with any behavioral health organization although this association was only significant 
at the p<.1 level. Regression results of the 3 outcome variables for all sensitivity analyses were 
very similar to the main analysis (see Table B.1-B.3 for results of sensitivity analyses). 
2.3.5 Variance attributable to explanatory variables  
In total, our explanatory variables accounted for a 45.7% reduction of the total variance for 
number of ingredients, 21.1% for share of most preferred ingredient, and 28.0% for HHI (Table 
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2.4). Adjusting for all explanatory variables, organizational-level influence on unexplained 
variation in psychiatrists’ antipsychotic prescribing was very small (results not shown). This 
variability obtained from the multiple membership modeling is not constant; rather, it varies 
across psychiatrists by their weighting schemes.82 For example, for a psychiatrist who was 
affiliated with only 1 organization during the study period, organizational-level influence only 
explained 8% of the variance in number of ingredients, 1.5% in share of most preferred 
antipsychotic ingredient, and 4% of the unexplained total variance in HHI. The remaining 
portion of the variation was attributable to physician- and patient-level impacts (which could not 
be disentangled because analysis unit was at the physician-level). 
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Table 2.4: Predictors of the concentration of psychiatrist prescribing of antipsychotics and 
related variance reduction 
 
Variables 
Coefficients (standard errors) 
Number of 
ingredients 
Share of most 
preferred 
ingredient 
HHI of ingredients 
Characteristics of provider’s treated patients    
 
Share of female patients (%) -0.01 (0.01) 0.02 (0.03) 3.80 (2.24)* 
 
Share of SSI-eligible patients (%) 0.02 (0.01)** -0.16 (0.03)*** -13.15 (2.32)*** 
 
Share of non-Hispanic whites (%) 0.00 (0.00) -0.03 (0.02)* -2.11 (1.26)* 
 
Share of patients <18 years old (%) -0.03 (0.00)*** 0.07 (0.02)*** 8.01 (1.61)*** 
 
Share of patients ≥50 years old (%) 0.00 (0.01) -0.08 (0.04)** -5.59 (3.03)* 
 
Share of patients with serious mental illnesses 
 
0.02 (0.01)*** -0.11 (0.03)*** -9.00 (2.26)*** 
 
Share of patients with 2+ non-mental 
  
0.01 (0.01) 0.06 (0.04) 3.71 (3.08) 
 
Share of patients enrolled in fee-for-services 
 
0.00 (0.00) 0.02 (0.01) 1.79 (1.09)* 
Physician characteristics 
   
 
Physician sex (ref = male) 
   
  
Female -0.29 (0.18)* 1.23 (0.8) 97.53 (58.88)* 
 
Physician age (ref = <40) 
   
  
40–49 0.17 (0.25) 1.05 (1.14) 62.46 (83.84) 
  
50–59 -0.05 (0.25) 1.24 (1.13) 76.55 (82.87) 
  
≥60 0.25 (0.27) 1.92 (1.22) 103.37 (89.74) 
 
Attended medical school (ref = ranked ≥21) 
   
  
US top 20 -0.26 (0.30) 1.90 (1.33) 131.32 (97.92) 
  
Foreign schools 0.11 (0.17) 1.41 (0.76)* 62.29 (55.98) 
 
Total number of antipsychotic prescriptions 0.00 (0.00)*** 0.00 (0.00)*** -0.22 (0.03)*** 
 
Number of other antipsychotic prescribers in the same organizations (ref = 0) 
 
  
1–9 0.18 (0.33) 0.06 (1.46) -66.56 (107.72) 
  
≥10 0.34 (0.34) 1.26 (1.47) -33.44 (109.88) 
 
Practice location (ref = otherwise) 
   
  
Urban only -0.24 (0.27) 0.78 (1.21) 41.23 (88.81) 
Organizational setting 
   
 
Organization specialty (ref = otherwise) 
   
  
Any affiliation with a behavioral health 
 
0.79 (0.45)* 1.42 (1.96) 46.82 (145.66) 
 
Organizational affiliation type (ref = outpatient only) 
  
  
Inpatient only 0.36 (0.49) 2.74 (2.08) 135.78 (155.89) 
  
Both inpatient and outpatient 0.06 (0.28) 1.50 (1.22) 101.45 (90.76) 
 
Organization size  0.00 (0.00) 0.00 (0.00) 0.05 (0.07) 
Intercept 5.09 (0.96)*** 50.84 (4.24)*** 3751.94 (312.75)*** 
Variance reduction by adding above explanatory variables 
Total variation reduction 45.68% 21.05% 28.02% 
*p<.1, **p<.05, ***p<.01. 
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A. By share of patients with serious mental illnesses 
 
 
 
 
 
 
B. By share of SSI-eligible patients 
 
 
 
 
 
 
*All measures were adjusted for patient population, physician, and organizational setting covariates listed 
in the regression. 
 
Figure 2.1: Concentration of antipsychotics prescribing by psychiatrist's share of patients 
with serious mental illnesses, share of SSI-eligible patients* 
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 DISCUSSION 2.4
Our study provides a comprehensive assessment of how the diversity of psychiatrists’ 
antipsychotic choice is shaped by patient, physician, and organizational characteristics. We 
found that psychiatrist antipsychotic prescribing behavior was relatively concentrated within 
physicians in a large state Medicaid program. However, the degree of concentration in 
antipsychotic prescribing varied substantially across psychiatrists. Of the 3 types of factors 
examined in our study, several characteristics of the treated patient population and physicians 
were significantly associated with psychiatrists’ diversity vs. concentration of antipsychotic 
prescribing. The few characteristics of organizations we were able to measure had little influence 
over psychiatrist prescribing behavior. 
Previous studies have suggested that physicians rely heavily on preferred medications in 
multiple therapeutic classes.52,54 Three studies have examined physician antipsychotic 
prescribing previously; all used the IMS Health’s XponentTM database which has comprehensive 
information on physician prescribing but limited patient information. Taub and colleagues65 
found antipsychotic prescribing was quite concentrated for physicians who wrote ≥12 
antipsychotic prescription – with a mean HHI of 4,612 for primary care providers and of 3,245 
for psychiatrists in 2007. Donohue and colleagues,55 using 2002-2007  data for physicians with 
≥20 antipsychotic prescriptions per year, found the concentration of antipsychotic prescribing at 
the physician level decreased over time and reached a mean of 2,900 in 2007. Berndt and 
colleagues also found a mean HHI of 2,900 for physicians with ≥50 antipsychotic prescriptions 
in 2007.92  Using Medicaid data from a more recent time period (2011), measuring concentration 
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in three ways, and adjusting for a comprehensive set of factors, our study also finds that 
antipsychotic prescribing was relatively concentrated and varied substantially across 
psychiatrists. By focusing on psychiatrists with at least 10 antipsychotic users in the year, we 
were able to evaluate the degree of concentration for those who were regular antipsychotic 
prescribers and accounted for most of the antipsychotic prescriptions by psychiatrists. 
Our finding that there was substantial variability in the degree of concentration in 
antipsychotic prescribing across psychiatrists suggests that patients seeing psychiatrists who only 
prescribe a limited number of antipsychotics may have a very different treatment experience than 
do patients whose doctors prescribe a wide range of antipsychotic products. Antipsychotics have 
been approved to treat several serious mental disorders (such as schizophrenia and major 
depressive disorder), which usually need multiple trials before finding the “best drug” for a 
particular patient. For instance, the Clinical Antipsychotic Trials of Intervention Effectiveness 
(CATIE) found that 74 percent of patients with schizophrenia failed the first trial,93 indicating 
that the majority of patients with schizophrenia would need at least 2 trials and that patients with 
treatment-resistant schizophrenia would need more.94 Psychiatrists’ willingness to use a wide 
range of choices may potentially lead to better health outcomes through customizing prescribing 
choices to individual patients.52,53 Our finding that a sizable psychiatrists (15%) treating 
Medicaid enrollees with antipsychotics had very concentrated prescribing behavior (e.g., relied 
heavily on only one or two antipsychotic agents) indicates that some psychiatrists may be limited 
in their ability to tailor treatment to individual patient needs and preferences.  
To our knowledge, this study is the first to examine the concentration of antipsychotic 
prescribing with all three levels of information on physicians: characteristics of the physicians, 
their treated patients and practice settings. Previous research found that patient clinical factors 
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played trivial role in medication switches.54 Our study found a significant relationship between 
patients’ characteristics and the diversity of physicians’ prescribing of antipsychotics although 
effects were relatively small. Psychiatrists had more diversified prescribing using all three 
measures of concentration if they had a higher share of patient population with a disability or 
with more severe mental illnesses. Of the several physician characteristics examined, female 
psychiatrists tended to have slightly more concentrated prescribing behavior than their male 
counterparts although the association was only marginally significant. Our organization-level 
factors were only limited to organization type, specialty, and size. Psychiatrists who had any 
affiliation with a behavioral health organization (clinic or psychiatric hospital) were associated 
with prescribing more unique ingredients than those not affiliated with behavioral health 
organizations although it was only marginally significant. We did not have information on other 
organizational factors such as quality improvement initiatives, financial incentives, and guideline 
dissemination which may also play an important role The fact that the explanatory variables 
included in the regressions accounted for a moderate reduction of the total variance for the 3 
outcome measures (28.0%-45.7%) implies that some other factors not included in our analyses 
also influence physicians’ antipsychotic prescribing behavior. 
This study has several limitations. First, our study examined prescribing behavior in the 
Pennsylvania Medicaid program and thus our findings may not necessarily be generalizable to 
other states. Second, the HCOSTM database captures every healthcare organization and provider 
that is part of a health system, but it seldom includes small practices with only 1-2 providers. 
Third, although we adjusted for 3 types of factors likely to affect prescribing, we had a limited 
number of organization-level characteristics. In addition, we could not adjust for other important 
factors, such as physician belief and pharmaceutical manufacturer promotion on specific 
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antipsychotic drugs, which might also shape physician prescribing behavior.55,95 Furthermore, we 
were unable to measure the severity of illness using the administrative data so we included 
information such as disability and comorbidity status. Finally, approximately 23% of our patient 
sample was <18. Psychiatrists prescribing primarily to children may be more concentrated in 
their prescribing because fewer antipsychotics are approved for use in children. However, given 
that two thirds of psychiatrists in our sample treated both adults and children we addressed this 
issue by including a variable for the share of patients <18 in all the regressions. This variable had 
very small effect on prescribing concentration. 
Using the multiple membership modeling approach –a new method that has been rarely 
applied in health services research -- to capture the real-life data structure, we found that 
antipsychotic prescribing behavior by individual psychiatrists in a large state Medicaid program 
was relatively concentrated but it varied substantially across psychiatrists. Health systems may 
consider exploring strategies for educating providers or guiding patients to providers with greater 
ability to tailor treatment decisions. 
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3.0  PRESCRIBING OF CLOZAPINE AND ANTIPSYCHOTIC POLYPHARMACY 
FOR SCHIZOPHRENIA IN A LARGE MEDICAID PROGRAM 
Yan Tang, Marcela Horvitz-Lennon, Walid F. Gellad, Judith R. Lave, Sharon-Lise T. Normand, 
Julie M. Donohue 
 
ABSTRACT 
Objectives: Poor response to antipsychotic treatment for schizophrenia may be due in part to 
poor quality prescribing. In particular, there is underuse of clozapine, the only antipsychotic 
approved for treatment-resistant schizophrenia, and overuse of non-clozapine antipsychotic 
polypharmacy, a non-evidence based treatment that may result in undesirable consequences 
including symptom persistence/deterioration, hospitalization and unnecessary healthcare costs. 
Non-clozapine antipsychotic polypharmacy (hereafter, antipsychotic polypharmacy) may in fact 
be used by some providers as a substitute for clozapine in the management of treatment-resistant 
schizophrenia. However, few studies of these prescribing practices have been conducted at the 
provider-level. We evaluated the prevalence of and relationship between clozapine and 
antipsychotic polypharmacy prescribing at the provider-level in a large Medicaid program. We 
also examined patient- and provider-level factors associated with these prescribing practices.  
Methods: Using 2010-2012 data from Pennsylvania’s Medicaid we identified providers 
regularly prescribing antipsychotics to patients with schizophrenia (defined as 10 or more 
nonelderly Medicaid patients without Medicare coverage). We characterized providers’ patients 
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and payers (managed care vs. fee-for-service) using Medicaid data, and providers’ demographics 
using the National Provider Identifier file from the Centers for Medicare and Medicaid Services. 
We measured provider-level share of patients with clozapine use and antipsychotic 
polypharmacy use per year. Antipsychotic polypharmacy was defined as more than 90 days’ 
concurrent use of ≥2 non-clozapine antipsychotics, allowing for gaps of up to 32 days in days’ 
supply for the same medication. We used descriptive analyses and generalized estimating 
equations with a binomial distribution and a logit link to examine clozapine and antipsychotic 
polypharmacy practices and associated factors at the level of patients (e.g., demographics, 
comorbidities, fee-for-service vs. managed care plans) and providers (e.g., high vs. low 
prescribing volume, sex, specialty). We included year indicators to adjust for time effects. 
Results: The analytic cohort included 645 prescribers in 2010, 632 in 2011, and 650 in 2012. 
Provider-level clozapine and antipsychotic polypharmacy practices were relatively stable over 
time. In 2012, provider-level mean shares of patients with clozapine and antipsychotic 
polypharmacy use were 6.9% (range: 0%-88.9%) and 7.0% (range: 0%-45.2%), respectively. A 
sizable proportion of providers prescribed antipsychotic polypharmacy but not clozapine in each 
study year (e.g., 15.5% in 2012). Clozapine and antipsychotic polypharmacy prescribing were 
not inversely correlated at the provider-level. High volume prescribers were much more likely to 
prescribe both clozapine (OR = 1.43, 95% CI, 1.22-1.67, p<0.01) and antipsychotic 
polypharmacy (OR = 2.65, 95% CI, 2.29-3.05, p<0.01) than low volume prescribers. Primary 
care providers, who made up 5.7% of our sample in 2012, were substantially less likely than 
psychiatrists to prescribe clozapine (OR = 0.55, 95% CI, 0.36-0.84, p<0.01) but just as likely to 
antipsychotic polypharmacy. We found significant associations between several patient-level 
characteristics and these prescribing practices. 
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Conclusions: Antipsychotic polypharmacy is used as much as clozapine in the care of Medicaid 
beneficiaries with schizophrenia, but many prescribers only use the former; prescribing volume, 
provider specialty, certain patient characteristics and predominant managed care plan appear to 
influence prescribing practices. Clinical and policy initiatives are needed to improve providers’ 
knowledge of clozapine and increase its use while decreasing use of antipsychotic 
polypharmacy. Our results suggest that targeting these initiatives to antipsychotic prescribers 
who use more antipsychotic polypharmacy than clozapine holds particular promise. 
 
Key words: clozapine, antipsychotic polypharmacy, prescribing, schizophrenia, Medicaid 
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 INTRODUCTION 3.1
Schizophrenia is a serious and chronic mental disorder associated with a heavy burden on the 
patient and the society.96  Antipsychotics -- a central component for the treatment of 
schizophrenia -- are mainly financed by Medicare and state Medicaid programs. The widespread 
substitution of second-generation for first-generation antipsychotics resulted in substantial 
growth in expenditures for antipsychotics in the 1990s.59 According to IMS Health’s analysis, 
$16.1 billion was spent on antipsychotic drugs in 2010, making them one of the top 5 therapeutic 
classes based on total spending.97 
The growing use of second-generation antipsychotics (SGAs) has raised concerns about 
the quality of care. Although SGAs were perceived to be more effective with fewer adverse 
effects than first-generation antipsychotics (FGAs), large clinical trials including the Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) found that (1) SGAs are associated 
with undesirable risks and (2) non-clozapine SGAs are no more effective than their first-
generation counterparts.93,98,99 Evidence also suggests high rates of failure on the first trial of 
antipsychotics among patients with schizophrenia. For example, CATIE found that 74 percent of 
patients failed the first trial,93 indicating that the majority of patients with schizophrenia would 
need at least 2 trials and that patients with treatment-resistant schizophrenia would need more.94 
The prevalence of treatment-resistant schizophrenia is approximately 30%,100 with resistance 
rates of up to 60% if using broader definitions to characterize patients with schizophrenia who do 
not respond to adequate trials of antipsychotics.101,102 Providers may turn to higher risk therapies 
for treatment-resistant schizophrenia. Because clozapine has superior efficacy than other 
antipsychotic drugs based on results from randomized controlled trials and meta analyses,104-108 
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clinical guidelines recommend clozapine for treatment-resistant schizophrenia and recurrent 
suicidal behavior.94,103 Nevertheless, physicians are reported to be reluctant to use 
clozapine.109,110 However, despite a lack of supporting evidence and high cost,111 there is a 
widespread practice of non-clozapine antipsychotic polypharmacy.112,113 Previous studies found 
patient-level prevalence of antipsychotic polypharmacy ranging from 7%-50%,114,115 depending 
on definition of antipsychotic polypharmacy. Non-clozapine antipsychotic polypharmacy 
(hereafter, antipsychotic polypharmacy)  has been used as a substitute for clozapine for the 
management of treatment-resistant schizophrenia.116 Underuse of clozapine which is evidence-
based practice and overuse of antipsychotic polypharmacy which is an unsupported practice may 
result in undesirable consequences such as side effects, medication non-adherence, 
hospitalization, and unnecessary health care costs.116,117  
Quality improvement and cost control in schizophrenia care and antipsychotic prescribing 
is largely dependent on the ability to alter providers’ prescribing behavior. However, little is 
known about prescriber-level prevalence of either evidence-based or unsupported antipsychotic 
prescribing practices. Little is also known about which factors are associated with those 
practices. To shed light on these issues, we examined providers’ use of clozapine and 
antipsychotic polypharmacy in Pennsylvania Medicaid from 2010-2012. In particular, we 
evaluated the prevalence of and relationship between clozapine and antipsychotic polypharmacy 
prescribing. We hypothesized that prescribing of clozapine and antipsychotic polypharmacy 
might be inversely correlated at the provider-level; that providers with little or no use of 
clozapine might have higher rates of antipsychotic polypharmacy and vice versa. We also 
examined patient- and provider-level factors associated with these prescribing practices. 
 55 
 METHODS 3.2
3.2.1 Data sources  
We obtained data from the Pennsylvania’s Department of Public Welfare (DPW) for all 
beneficiaries enrolled in Pennsylvania’s Medicaid program for calendar years 2010 to 2012. In 
each year, approximately 2.2 million individuals were enrolled either in the fee-for-service (FFS) 
or in managed care programs. The pharmacy claims file has information for each prescription 
claim including date of fill, days’ supply, medication dose, quantity, form, the National Drug 
Code (NDC), and prescribing provider Medicaid identifier. We obtained antipsychotics’ 
information on drug name, active ingredient, dose for each NDC from the Medi-Span® 
database.70 We used the medical claims files (e.g., inpatient, outpatient, professional) to identify 
diagnoses associated with inpatient or outpatient facility claims or provider visits. We used the 
enrollment file to capture beneficiary’s demographic and enrollment information such as age, 
sex, race/ethnicity, eligibility type, dual eligible status, enrolled health insurance plan (individual 
managed care plans vs. FFS). We obtained prescribing provider’s National Provider Identifier 
(NPI), name, and ZIP code for practice settings from the provider file from DPW.  
Using the NPI, we linked prescribing providers in Pennsylvania’s Medicaid data to the 
National Plan and Provider Enumeration System’s (NPPES) National Provider Identifier (NPI) 
file from the Centers for Medicare and Medicaid Services (CMS) to obtain each provider’s sex 
and specialty.118  
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3.2.2 Study sample  
The unit of analysis was at the provider-level; however, we started with a sample of claims at the 
patient-level from which we identified antipsychotic prescribers treating these patients. First, we 
limited Medicaid beneficiaries to nonelderly adults (18-64 years old) who were not dually 
eligible for Medicare. We excluded dual eligible beneficiaries because Medicaid data do not 
contain complete claims information for those enrollees, particularly for prescription drugs. 
Using inpatient, outpatient, and professional claims files, we then identified patients with ≥1 
inpatient or ≥2 outpatient claims with a primary or secondary diagnosis of schizophrenia (ICD-9 
codes: 295.xx) during a one-year period. We further restricted the sample to those with at least 
one prescription fill of antipsychotic drugs that year. We then identified all provider IDs 
associated with this patient sample.  Finally, we limited our analyses to individual providers 
(both psychiatrists and non-psychiatrist providers) regularly prescribing antipsychotics, defined 
as having at least 10 patients with a diagnosis of schizophrenia per year. We did not restrict the 
study sample to psychiatrists because non-psychiatrist providers (primary care providers and 
other) included in this analysis were regular prescribers who treated at least 10 patients with 
schizophrenia and prescribed a lot of antipsychotic prescriptions (mean number of annual 
prescriptions by primary care providers was about 100 in 2012). By including both psychiatrist 
and non-psychiatrist prescribers in this study, we expected to reflect the typical prescribing 
practices for antipsychotic drugs in the treatment of schizophrenia. 
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3.2.3 Dependent variables 
The two dependent variables calculated at the prescriber-level were the share of patients with any 
clozapine use and the share of patients with antipsychotic polypharmacy in a calendar year. 
Antipsychotic polypharmacy was defined as more than 90 days’ concurrent use of ≥2 non-
clozapine antipsychotics, allowing for gaps of up to 32 days in days’ supply for the same 
medication. Oral and depot formulations for the same drug were considered to be same 
medication. This definition of antipsychotic polypharmacy is a validated measure with excellent 
specificity and positive predictive value, compared to alternative measures of antipsychotic 
polypharmacy (e.g., 14, 60, or 90 days concurrent use, allowing gaps of up to 0, 14, or 32 
days).114 Based on recommended dosing intervals, we imputed days supply for long-acting 
injectable antipsychotic drugs as follows: risperidione injectable (Risperdal Consta) – 14 days, 
fluphenazine decanoate (Prolixin decanoate) – 21 days, and haloperidol decanoate (Haldol 
decanoate) – 28 days. 
3.2.4 Explanatory variables 
We examined the association between patient characteristics, payer (individual managed care 
plans vs. FFS), and provider characteristics and prescribing of clozapine and antipsychotic 
polypharmacy. Patient characteristics were first assessed at the patient-level and then aggregated 
to the provider-level. For example, for each antipsychotic prescriber we calculated the share of 
his or her patients in certain demographic and racial/ethnic groups (share that were female, share 
that were Hispanic, and share that were non-Hispanic black). We included a variable for the 
mean age of the provider’s patients. We included a measure of the share of patients eligible for 
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Medicaid through Supplemental Security Income (SSI) to measure disability status. To adjust for 
patients’ comorbidities and health status, we calculated each provider’s share of patients with 
affective disorders (ICD-9 codes: 296.xx, 300.4, 301.13, 309.1, 311), share with anxiety 
disorders (ICD-9 codes: 300.0, 309.81, 300.2, 300.3), share with other psychiatric disorders 
(ICD-9 codes: 307.1, 307.50, 307.51, 314), share with substance use disorders (ICD-9 codes: 
291, 292, 303, 304, 305.0, 305.2-305.7, 305.9), share with brain/cognitive impairment 
comorbidity (ICD-9 codes: 331, 797, 290, 294, 310, 317-319), and share with a schizophrenia-
related hospitalization. To capture the patient population’s non-mental health comorbidities, first, 
for each patient we constructed separate indicators of the 25 non-mental illnesses incorporated in 
the Elixhauser comorbidity index (a widely used comorbidity measure)79-81 based on patient’s 
medical claims. We then created a variable for the mean number of non-mental health 
comorbidities of the provider’s patients, which had a mean of 2 at the provider-level. 
Pennsylvania Medicaid runs a fee-for-service program for approximately 25%-30% of 
enrollees and contracts with multiple managed care organizations and managed behavioral health 
organizations to manage care for the remaining 70%-75%. Managed care organizations may 
adopt different policies with respect to coverage and utilization management tools applied to 
antipsychotics. We constructed two measures to capture the influence on a provider’s prescribing 
behavior of these different policies. The first measure was the number of unique managed care 
organizations in which the provider’s patient population was enrolled. The second measure was a 
series of dummy variables indicating the managed care organization with the highest enrollment 
among the provider’s patient population with the fee-for-service serving as the reference 
category.  
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To estimate the association between provider characteristics and our prescribing 
outcomes we included provider’s prescribing volume, sex, specialty (psychiatrist, primary care 
provider, other), and practice location (urban only vs. otherwise).66,67,74 We defined prescribing 
volume as the number of antipsychotic prescriptions written for patients with schizophrenia per 
year. We classified prescribing volume into two groups: low vs. high prescription volume (split 
by the median value). In addition, we included year indicators to control for potential time trend. 
3.2.5 Statistical analysis  
For each year we reported provider-level prevalence of clozapine prescribing and antipsychotic 
polypharmacy prescribing, overall and stratified by prescription volume and specialty. To 
examine the association between clozapine and antipsychotic polypharmacy practices at the 
prescriber level, we created scatter plots of the two outcome variables as well as the Lowess 
smoothed curve of the two outcomes, which is a robust nonparametric method using localized 
subsets of the data to describe underlying relationship between variables.119 A Spearman’s rank 
correlation coefficient (rho) was calculated to examine the correlation between the two outcome 
variables. 
To account for repeated measures made for the same antipsychotic prescriber over the 3-
year study period, we used generalized estimating equations (GEE) with robust estimation of 
standard errors and an unstructured correlation matrix to examine provider’s clozapine and 
antipsychotic polypharmacy practices. We used a binomial distribution with a logit link to handle 
the two percentage variables which had a skewed distribution and many providers with zero 
values. This strategy has been applied widely in economic and health services research where 
outcomes are a continuous percentage.120-122 We also calculated marginal effects for provider’s 
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antipsychotic prescribing volume which was found to be significantly associated with the 
outcomes of interest, adjusting for all other explanatory variables.  
We performed sensitivity analyses with alternative specifications. First, we restricted the 
study sample to a subset cohort who appeared in all 3 years (i.e., balanced data). Second, we 
conducted an analysis restricting the sample to psychiatrists – the main prescribers of 
antipsychotic drugs in the U.S. Third, we considered a sensitivity analysis by including a 
categorical variable indicating the provider’s practice county (Philadelphia, Allegheny, other) 
because about half of the providers practiced in Philadelphia and Allegheny counties – the top 2 
most populous counties in Pennsylvania. In addition, to examine the impact of case mix with 
respect to treatment-resistant schizophrenia which we could not observe in claims data, we 
described variations in clozapine and antipsychotic polypharmacy prescribing stratified by share 
of patients with schizophrenia-related hospitalization, which we used as a proxy for treatment-
resistant schizophrenia. 
 RESULTS 3.3
In our study sample, there were 645 antipsychotic prescribers treating 14,072 patients with 
schizophrenia in 2010, 632 prescribers treating 13,606 patients in 2011, and 650 prescribers 
treating 13,559 patients in 2012 in Pennsylvania Medicaid program. Of the 892 unique providers 
prescribing antipsychotics in our study sample, 426 (47.8%) appeared in all 3 years. The 
characteristics of sample providers and their patients were very similar across the three year 
period so we present only the most recent year’s characteristics in Table 3.1. In 2012, the mean 
share of patients with schizophrenia-related hospitalization was 43.3%. The mean number of 
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managed care organizations in which a provider’s schizophrenia patients were enrolled was 4.5, 
and the mean share of patients enrolled in the fee-for-service program was 17.5%. Of the 650 
antipsychotic prescribers in 2012, 32% were female providers, and the majority (83.5%) were 
psychiatrists. 
 
Table 3.1: Characteristics of antipsychotic prescribers, 2012 
 
Characteristic  Mean (SD) or percent 
N  650 
Characteristics of provider's treated patients  
 Demographic information  
  Share of female patients (%) 44.51 (13.53) 
  Share of SSI-eligible patients (%) 91.75 (8.75) 
  Share of Hispanic patients (%) 9.12 (15.92) 
  Share of non-Hispanic black patients (%) 37.08 (28.61) 
  Mean age of patients 42.17 (5.12) 
 Health status and hospitalization  
  Share of patients with affective disorders (%) 66.14 (19.27) 
  Share of patients with anxiety disorders (%) 32.46 (16.46) 
  Share of patients with other psychiatric disorders (%) 4.80 (6.31) 
  Share of patients with substance use disorders (%) 39.31 (22.64) 
  Share of patients with brain impairment comorbidity (%) 10.85 (10.46) 
  Mean number of non-mental health comorbidities 2.09 (0.71) 
  Share of patients with schizophrenia-related hospitalization (%) 43.26 (23.57) 
 Health insurance   
  Number of plans for treated patients* 4.48 (1.89) 
  Share of patients enrolled in FFS other than MCOs (%) 17.54 (30.21) 
Provider characteristics   
 Number of antipsychotic prescriptions 230.58 (266.53) 
 Female  32.00% 
 Specialty   
 Psychiatrist  83.54% 
 Primary care provider 5.69% 
 Other  10.77% 
  Practice in urban only  93.69% 
*Number of plans counted unique plans across all patients treated by the provider (i.e., FFS or each 
managed care plan was counted as 1 plan). 
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Table 3.2(A) displays the provider-level clozapine and antipsychotic polypharmacy 
practices from 2010-2012, which were relatively stable over time. In 2012, 60.2% of 
antipsychotic prescribers had any clozapine prescribing and 57.9% had any antipsychotic 
polypharmacy. Notably, among high volume providers 90.8% of antipsychotic prescribers used 
polypharmacy for at least one patient while only 77.4% used clozapine in 2012. At the provider-
level, the mean share of patients with clozapine use was 6.9%, with a range across providers 
from 0.0% to 88.9%. The mean share of patients with antipsychotic polypharmacy was 7.0% in 
2012 which varied across provider from 0.0% to 45.2%. Both the share of patients with 
clozapine use and share with antipsychotic polypharmacy use were much lower among low 
volume providers than among their high volume counterparts. Table 3.2(B) shows the two 
practices by specialty. In 2012, the prevalence of any clozapine prescribing was 63.0% among 
psychiatrists versus 29.7% among primary care providers. In contrast, the difference in any 
antipsychotic polypharmacy was relatively smaller (58.8% for psychiatrists vs. 51.4% for 
primary care providers in 2012). Primary care providers had higher share of patients with 
antipsychotic polypharmacy than that for clozapine while psychiatrists had similar shares for the 
two practices. As shown in Table C.1, we also examined variation in clozapine and 
antipsychotic polypharmacy prescribing by quartiles of schizophrenia-related hospitalization 
among provider’s patient population -- proxy for treatment-resistant schizophrenia. We did not 
find a positive correlation between schizophrenia severity and clozapine and antipsychotic 
polypharmacy practices. In fact, providers in the highest quartile were much less likely to use 
antipsychotic polypharmacy than their counterparts in lower quartiles. 
 63 
Table 3.2: Provider clozapine and antipsychotic polypharmacy practices, 2010-2012 
 
 
A. By antipsychotic prescribing volume* 
 
Year 
 
N 
providers 
N antipsychotic 
prescriptions† 
Any 
clozapine 
prescribing 
(%) 
Any 
polypharmacy 
prescribing (%) 
Share of 
patients w/ 
clozapine use 
(%)† 
Share of 
patients w/ 
polypharmacy 
use (%)† 
  Overall    
2010 645 213.33 (246.79) 56.12 56.43 5.88 (9.13) 5.85 (7.51) 
2011 632 229.46 (271.90) 59.97 59.49 6.94 (10.4) 6.91 (8.56) 
2012 650 230.58 (266.53) 60.15 57.85 6.85 (9.72) 7.01 (8.60) 
   Low volume prescribers  2010 322 65.28 (30.83) 37.58 28.26 3.37 (6.19) 2.78 (5.49) 
2011 315 62.90 (33.98) 45.08 28.57 4.77 (7.59) 2.77 (5.27) 
2012 323 62.87 (34.69) 42.72 24.46 4.64 (8.15) 2.51 (5.26) 
   High volume prescribers  2010 323 360.93 (277.66) 74.61 84.52 8.37 (10.77) 8.91 (8.00) 
2011 317 394.96 (302.25) 74.76 90.22 9.09 (12.18) 11.03 (9.19) 
2012 327 396.24 (291.27) 77.37 90.83 9.04 (10.63) 11.46 (8.95) 
*We defined prescribing volume as the number of antipsychotic prescriptions written for provider’s 
patient population with schizophrenia. We classified prescribing volume into two groups: low vs. high 
prescription volume group, split by the median value. 
†Figures within parentheses are means and SDs. 
 
 
B. By provider specialty* 
 
Year N providers 
N antipsychotic 
prescriptions* 
Any 
clozapine 
prescribing 
(%) 
Any 
polypharmacy 
prescribing (%) 
Share of 
patients w/ 
clozapine use 
(%)* 
Share of 
patients w/ 
polypharmacy 
use (%)* 
   Psychiatrists    
2010 515 232.16 (267.34) 61.36 58.83 6.37 (9.19) 6.14 (7.60) 
2011 526 249.41 (288.50) 62.55 61.22 7.17 (10.56) 7.17 (8.72) 
2012 543 245.76 (282.28) 62.98 58.75 7.15 (9.97) 7.13 (8.56) 
   Primary care providers  
2010 86 122.88 (97.52) 30.23 40.70 2.58 (5.50) 3.98 (6.18) 
2011 41 80.98 (68.28) 36.59 36.59 3.18 (5.21) 3.47 (5.78) 
2012 37 98.59 (101.72) 29.73 51.35 2.06 (3.61) 5.78 (7.67) 
   Other    
2010 44 169.80 (128.51) 45.45 59.09 6.59 (12.37) 6.13 (8.44) 
2011 65 161.63 (145.51) 53.85 60.00 7.39 (10.98) 7.02 (8.31) 
2012 70 182.57 (152.88) 54.29 54.29 7.08 (9.42) 6.77 (9.43) 
*Figures within parentheses are means and SDs.
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We did not find evidence of inverse correlations between the share of patients with 
clozapine prescribing and the share of patients with antipsychotic polypharmacy at the provider-
level (Figure 3.1). Instead, the two outcome variables had a non-linear correlation based on the 
Lowess smoothed curve and had a correlation of 0.31 in 2012 according to Spearman’s rho 
coefficient. Notably, there was a sizable portion of providers who practiced antipsychotic 
polypharmacy but did not use any clozapine during the study period (Table 3.3). For example, of 
the 650 providers in 2012, 101 (15.5%) used zero clozapine but prescribed polypharmacy for at 
least one patient (mean share of patients with polypharmacy use among these providers was 
11.6%), and 46 (7.1%) providers (without any clozapine use) had at least 10% of their patients 
on polypharmacy (mean share of patients with polypharmacy was 18.5%). 
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Figure 3.1: Association between clozapine and antipsychotic polypharmacy practices by 
antipsychotic prescribers, 2012 
 
 
 66 
Table 3.3: Antipsychotic polypharmacy prescribing among providers with no clozapine 
use, 2010-2012* 
 
Year Total N providers 
No clozapine prescribing 
Any patient w/ polypharmacy use ≥10% of patients w/polypharmacy use 
N providers 
(percent) 
Share of patients 
with polypharmacy 
use (%)† 
N providers 
(percent) 
Share of patients with 
polypharmacy use (%)† 
   Overall   
2010 645 116 (17.98%) 10.44 (7.21) 45 (6.98%) 17.21 (7.16) 
2011 632 124 (19.62%) 11.11 (8.04) 56 (8.86%) 17.82 (7.40) 
2012 650 101 (15.54%) 11.63 (7.94) 46 (7.08%) 18.46 (6.76) 
   Low volume prescribers  
2010 322 55 (17.08%) 10.03 (6.32) 20 (6.21%) 16.01 (6.95) 
2011 315 52 (16.51%) 10.17 (5.41) 23 (7.30%) 15.04 (4.34) 
2012 323 39 (12.07%) 11.07 (6.32) 18 (5.57%) 16.41 (5.30) 
   High volume prescribers  
2010 323 61 (18.89%) 10.81 (7.95) 25 (7.74%) 18.18 (7.31) 
2011 317 72 (22.71%) 11.78 (9.49) 33 (10.41%) 19.76 (8.46) 
2012 327 62 (18.96%) 11.98 (8.83) 28 (8.56%) 19.78 (7.34) 
* We defined prescribing volume as the number of antipsychotic prescriptions written for provider’s 
patient population with schizophrenia. We classified prescribing volume into two groups: low vs. high 
prescription volume group, split by the median value. 
†Figures within parentheses are means and SDs. 
 67 
Table 3.4 shows the regression results from the GEE models. Controlling for all other 
factors, when seeing a patient with schizophrenia, antipsychotic prescribers with a larger share of 
Hispanic patients were less likely to prescribe clozapine [odds ratio (OR) per 10% increase = 
0.81, 95% confidence interval (CI), 0.75-0.88, p<0.01] and antipsychotic polypharmacy (OR per 
10% increase = 0.89, 95% CI, 0.84-0.95, p<0.01) than those with a smaller share of Hispanic 
patients. Similar effects were found for providers with different shares of non-Hispanic black 
patients. Prescribers who had a larger share of patients with schizophrenia-related hospitalization 
had greater odds of clozapine prescribing (OR per 10% increase = 1.10, 95% CI, 1.04-1.15, 
p<0.01) and lower odds of antipsychotic polypharmacy prescribing (OR per 10% increase = 
0.91, 95% CI, 0.88-0.95, p<0.01) to their patients than prescribers with a smaller share of 
patients who had a schizophrenia-related hospitalization. 
There was significant variation in antipsychotic prescribing across providers based on 
their patients’ predominant plan – 2 managed care plans were significantly different from FFS in 
clozapine prescribing while 5 managed care plans deviated from FFS in antipsychotic 
polypharmacy prescribing (Table 3.4). For example, prescribers with MCO plan I as the 
predominant plan were much more likely to prescribe clozapine when seeing a patient with 
schizophrenia than prescribers with FFS as the most popular plan (OR = 1.68, 95% CI, 1.00-
2.80, p<0.05). Prescribers with MCO plan A as the predominant plan were more likely to 
prescribe antipsychotic polypharmacy than their counterparts with FFS (OR = 1.58, 95% CI, 
1.28-1.94, p<0.01). 
After adjustment for characteristics of treated patients and other covariates, primary care 
providers, who made up 5.7% of our sample in 2012, were substantially less likely than 
psychiatrists to prescribe clozapine to their patients (OR = 0.55, 95% CI, 0.36-0.84, p<0.01). 
 68 
Provider specialty was not significantly associated with the prescribing of antipsychotic 
polypharmacy. Controlling for all other covariates, high volume prescribers were much more 
likely to prescribe clozapine (OR = 1.43, 95% CI, 1.22-1.67, p<0.01) and antipsychotic 
polypharmacy (OR = 2.65, 95% CI, 2.29-3.05, p<0.01) than their low volume counterparts. As 
shown in Figure 3.2, the predicted share of patients with clozapine use would be 4.1% for low 
volume prescribers and 5.8% for high volume prescribers. The predicted share of patients with 
antipsychotic polypharmacy would vary from 2.8% for low volume prescribers to 7.2% for their 
high volume counterparts. Sensitivity analyses reported very similar results as the main analysis 
(Table C.2-C.4). 
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Table 3.4: GEE regression results for all antipsychotic prescribers: predictors of clozapine 
and antipsychotic polypharmacy prescribing 
 
Variables 
Odds Ratios (robust standard error) 
Clozapine 
prescribing 
Antipsychotic 
polypharmacy 
prescribing 
Characteristics of provider's treated patients   
 Demographic information   
  Share of female patients (%) 1.00  (0.00) 1.00  (0.00) 
  Share of SSI-eligible patients (%) 1.02 (0.00)*** 1.02 (0.00)*** 
  Share of Hispanic patients (%) 0.98 (0.00)*** 0.99 (0.00)*** 
  Share of non-Hispanic black patients (%) 0.99 (0.00)*** 1.00 (0.00)* 
  Mean age of patients 0.98 (0.01)** 0.99 (0.01) 
 Health status and hospitalization   
  Share of patients with affective disorders (%) 0.98 (0.00)*** 1.00  (0.00) 
  Share of patients with anxiety disorders (%) 0.99 (0.00)** 0.99 (0.00)*** 
  Share of patients with other psychiatric disorders (%) 1.00 (0.01) 1.01 (0.01)* 
  Share of patients with substance use disorders (%) 0.99 (0.00)*** 0.99 (0.00)*** 
  Share of patients with brain impairment comorbidity (%) 1.00  (0.00) 1.01 (0.00)* 
  Mean number of non-mental health comorbidities 1.15 (0.07)** 1.11 (0.06)* 
  Share of patients with schizophrenia-related hospitalization (%) 1.01 (0.00)*** 0.99 (0.00)*** 
 Health insurance   
  Number of plans for treated patients 1.04 (0.02)* 0.96 (0.02)** 
      The predominant plan among patient population (ref = FFS)   
   MCO plan A 0.99 (0.15) 1.58 (0.17)*** 
   MCO plan B 0.87 (0.16) 1.46 (0.46) 
   MCO plan C 1.21 (0.17) 1.38 (0.14)*** 
   MCO plan D 2.30 (0.80)** 1.12 (0.49) 
   MCO plan E 0.94 (0.17) 0.75 (0.12)* 
   MCO plan F 1.45 (0.49) 1.11 (0.31) 
   MCO plan G 1.18 (0.19) 0.85 (0.11) 
   MCO plan H 1.19 (0.21) 1.54 (0.19)*** 
   MCO plan I 1.68 (0.44)** 1.46 (0.24)** 
   MCO plan J (combined)† 1.28 (0.30) 0.8 (0.33) 
Provider characteristics   
 High prescription volume (ref = low prescription volume) 1.43 (0.11)*** 2.65 (0.19)*** 
 Female  (ref = male) 1.07 (0.12) 1.01 (0.07) 
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Table 3.4 (Continued)   
Variables 
Odds Ratios (robust standard error) 
Clozapine 
prescribing 
Antipsychotic 
polypharmacy 
prescribing 
 Specialty (ref = psychiatrist)   
  Primary care provider 0.55 (0.12)*** 1.11 (0.20) 
  Other 1.01 (0.17) 0.85 (0.11) 
 Practice in urban only (ref=otherwise) 1.00 (0.19) 0.96 (0.13) 
Year (ref = 2010)   
 2011 1.02 (0.05) 1.15 (0.06)*** 
 2012 0.98 (0.07) 1.12 (0.06)** 
Intercept 0.06 (0.03)*** 0.04 (0.02)*** 
N obs 1,927 1,927 
N groups  892 892 
*p<.1, **p<.05, ***p<.01. 
†MCO plan J combined plans with only 1-3 observations in a year. 
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* All covariates included in the regression models were adjusted for the marginal effects calculation. 
 
Figure 3.2: Marginal effects of antipsychotic prescribing volume on providers' clozapine 
and polypharmacy practices* 
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 DISCUSSION  3.4
To our knowledge, this study is the first to assess provider-level clozapine and antipsychotic 
polypharmacy practices, using multiple years of managed care and fee-for-service program data 
from a large state Medicaid program. We found that providers who regularly prescribed 
antipsychotics to patients with schizophrenia used clozapine or antipsychotic polypharmacy in a 
small proportion of their patients. However, these prescribing practices varied tremendously 
across providers. In particular, a sizable proportion of providers (15.5% in 2012) prescribed 
antipsychotic polypharmacy but no clozapine. 
We found that provider-level share of patients with clozapine use varied from 0% to 
88.9% and share with antipsychotic polypharmacy use varied from 0% to 45.2% in 2012 (rates 
were relatively stable over time). When patients with schizophrenia do not respond to adequate 
trails of other antipsychotic agents, providers may turn to clozapine or antipsychotic 
polypharmacy. Although the prevalence of treatment resistance among patients with 
schizophrenia is approximately 30%,100  we cannot determine the share of treatment-resistant 
schizophrenia for a given provider using claims data. It is possible that providers who have 
higher prescribing of clozapine and antipsychotic polypharmacy have a higher share of their 
patients with treatment-resistant schizophrenia than providers who are less likely to engage in 
these prescribing practices. To address this issue, we examined clozapine and antipsychotic 
polypharmacy practices stratified by share of patients with schizophrenia-related hospitalization-
-a proxy for treatment-resistant schizophrenia (Table C.1). We did not find that providers in the 
higher quartiles of schizophrenia-related hospitalization had higher clozapine or antipsychotic 
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polypharmacy prescribing than their counterparts in the lower quartiles, suggesting that higher 
clozapine or antipsychotic polypharmacy practices are not due to higher share of patients with 
treatment-resistant schizophrenia. Notably, providers in the highest quartile of schizophrenia-
related hospitalization were much less likely to prescribe antipsychotic polypharmacy than their 
counterparts in the lower quartiles, indicating that providers with smaller proportion of patients 
with treatment-resistant schizophrenia actually were more likely to engage in antipsychotic 
polypharmacy prescribing than providers with higher caseloads of treatment-resistant 
schizophrenia. 
As the only antipsychotic medication approved by the U.S. Food and Drug 
Administration (FDA) to manage treatment-resistant schizophrenia and recurrent suicidal 
behavior, clozapine is significantly under-utilized in the treatment of schizophrenia 
patients.102,110,123 Our finding that providers who were regularly treating patients with 
schizophrenia prescribed clozapine, on average, to 6.9% of their patients points to underuse of 
clozapine in the Pennsylvania Medicaid program. Prescribers’ reluctance to use clozapine 
treatment might be due to their concern about the potential risk of metabolic adverse effects 
associated with clozapine use (e.g., weight gain, occurrence of diabetes and dyslipidemia),99 lack 
of awareness of clozapine’s benefits, or lack experience.109,110 Although it is reasonable to 
consider potential side effects of clozapine, previous literature indicates that providers have the 
tendency to overestimate the prevalence of side effects and risks associated with clozapine 
practices.102,109 Clinical guidelines suggest monitoring metabolic symptoms for patients using 
SGAs (including clozapine) to prevent premature mortality associated with antipsychotic 
use.99,124 However, the rates of monitoring are very low, ranging from 10% to 43%.125,126 Both 
primary care providers and psychiatrists reported factors such as time burden and difficulty in 
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collaborating with other providers as major barriers to metabolic monitoring.125,126 To increase 
clozapine use when appropriate and decrease associated side effects, quality initiatives may use 
educational interventions to improve prescribers’ knowledge of clozapine and also take efforts to 
promote better collaboration between providers for schizophrenia patients who use antipsychotic 
drugs. 
Compared to previous studies using various definitions of antipsychotic polypharmacy 
(e.g., concurrent prescribing of 2 or more antipsychotics with at least 14, 30, 60, or 90 days), we 
used the validated measure of antipsychotic polypharmacy with excellent specificity and positive 
predictive value.114 We found that providers prescribed non-clozapine antipsychotic 
polypharmacy to 7% of their patients in 2012 in Pennsylvania Medicaid. Our finding that a 
sizable portion of providers (e.g., 15.5% in 2012) used zero clozapine but prescribed 
antipsychotic polypharmacy to their patients points to problematic prescribing of antipsychotics 
among these prescribers -- they did not try any clozapine (the evidence-based drug) before using 
antipsychotic polypharmacy to their patient population. Because there is little research evidence 
suggesting patients with schizophrenia could benefit from non-clozapine antipsychotic 
polypharmacy practices, those providers prescribing more polypharmacy than clozapine 
(especially those who use zero clozapine) should be targeted for educational interventions. Also, 
it may be worthwhile steering treatment-resistant schizophrenia patients to prescribers who are 
willing to use clozapine. 
After adjustment for all other covariates, primary care providers were much less likely to 
prescribe clozapine than psychiatrists; however, they were just likely to practice antipsychotic 
polypharmacy. Compared to their psychiatrist counterparts, primary care providers treat patients 
with a much wider variety of conditions. Our finding of much lower clozapine use by primary 
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care providers than that by psychiatrists could be because primary care providers perceive 
clozapine to be very risky and thus they are less willing to prescribe it than their psychiatrist 
counterparts. Differences in clozapine prescribing could be also due to case mix by specialty -- 
primary care providers may treat fewer patients with treatment-resistant schizophrenia than 
psychiatrists. However, the second explanation is not supported by the finding of non-significant 
specialty difference in antipsychotic polypharmacy prescribing. In fact, primary care providers 
had higher share of patients with antipsychotic polypharmacy use than that for clozapine use, 
indicating that primary care providers appeared to perceive antipsychotic polypharmacy to be 
less risky than clozapine even though antipsychotic polypharmacy is a non-evidence based 
treatment. Given the widespread use of antipsychotic drugs in patients with schizophrenia 
(particularly in Medicaid because of the important role it plays in financing antipsychotics), it is 
important to understand the specialty differences in order to promote high quality of care in 
antipsychotic prescribing and schizophrenia treatment. 
Our study has several limitations. First, we examined prescribers’ clozapine and 
antipsychotic polypharmacy practices in the Pennsylvania Medicaid program and thus the 
findings may not necessarily be generalizable to other states. Second, to adjust for potential 
impact of patient case mix, we included a rich set of patients’ comorbidities and health status 
(including SSI status, several mental illness disorders, overall non-mental health comorbidity, 
and schizophrenia-related hospitalization); however, we could not determine share of patients 
with treatment-resistant schizophrenia for a given provider using claims data. Third, we had a 
limited number of provider-level characteristics (specialty, sex, prescription volume, and practice 
location). Other factors such as provider age and education background might also play a role in 
prescribing behavior of clozapine and antipsychotic polypharmacy. Finally, we could not adjust 
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for other important factors, such as pharmaceutical manufacturer promotion on specific 
antipsychotic drugs, which might affect physician prescribing choice.55  
In conclusion, we found provider-level underuse of clozapine and use of non-evidence 
supported practice of non-clozapine antipsychotic polypharmacy in this large Medicaid program. 
Quality initiatives may take actions to improve evidence-based practice and to decrease 
unsupported practices in the management of antipsychotic drug use. For example, educational 
interventions may be used to improve providers’ knowledge of clozapine. Also, academic 
detailing may target providers who use more antipsychotic polypharmacy than clozapine, 
particularly those who do not try any clozapine but use a lot of polypharmacy practices. It may 
also be worthwhile steering treatment-resistant schizophrenia patients to prescribers who are 
willing to use clozapine other than antipsychotic polypharmacy. 
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APPENDIX A: TABLES FOR CHAPTER 1 
Table A.1: List of drugs in the three drug categories, 2009* 
Drug category Drug class Generic name Brand name 
Antidepressants Generic drugs: 
Tricyclic Agents Amitriptyline HCL 
Antidepressants - Misc. Budeprion SR 
Antidepressants - Misc. Budeprion XL 
Antidepressants - Misc. Bupropion HCL 
Antidepressants - Misc. Bupropion HCL SR  
Antidepressants - Misc. Bupropion XL 
SSRIs Citalopram HBR 
Tricyclic Agents Clomipramine HCL 
Tricyclic Agents Desipramine HCL 
Tricyclic Agents Doxepin HCL 
SSRIs Fluoxetine HCL 
SSRIs Fluvoxamine Maleate 
Tricyclic Agents Imipramine HCL 
Tricyclic Agents Imipramine Pamoate 
Tetracyclics Mirtazapine 
Tricyclic Agents Nortriptyline HCl 
SSRIs Paroxetine HCl 
Tricyclic Agents Protriptyline HCL 
SSRIs Sertraline HCL 
MAOIs Tranylcypromine Sulfate 
Modified Cyclics Trazodone HCL 
SNRIs Venlafaxine HCL 
 
Brand drugs: 
 Tricyclic Agents Clomipramine HCL Anafranil 
Antidepressants - Misc. Bupropion HBR Aplenzin† 
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Table A.1 (Continued) 
  
Drug category Drug class Generic name Brand name 
 Tricyclic Agents Amoxapine Asendin 
 SSRIs Citalopram HCL Celexa 
 SNRIs Duloxetine HCL Cymbalta† 
 SNRIs Venlafaxine HCL Effexor 
 SNRIs Venlafaxine HCL Effexor XR† 
 MAOIs Selegiline Emsam† 
 SSRIs Escitalopram Oxalate Lexapro† 
 SSRIs Fluvoxamine Maleate Luvox CR 
 Antidepressants - Misc. Maprotiline HCL Maprotiline HCL 
 MAOIs Isocarboxazid Marplan 
 MAOIs Phenelzine Sulfate Nardil 
 Modified Cyclics Nefazodone HCL Nefazodone HCL 
 Tricyclic Agents Desipramine HCL Norpramin 
 Tricyclic Agents Nortriptyline HCL Pamelor 
 MAOIs Tranylcypromine Sulfate Parnate 
 SSRIs Paroxetine HCL Paxil 
 SSRIs Paroxetine HCL Paxil CR 
 SSRIs Paroxetine Mesylate Pexeva 
 SNRIs Desvenlafaxine Succinate Pristiq† 
 SSRIs Fluoxetine HCL Prozac† 
 Tetracyclics Mirtazapine Remeron† 
 Tricyclic Agents Trimipramine Maleate Surmontil 
 Tricyclic Agents Imipramine HCL Tofranil 
 Tricyclic Agents Imipramine Pamoate Tofranil-PM 
 Tricyclic Agents Protriptyline HCL Vivactil 
 Antidepressants - Misc. Bupropion HCL Wellbutrin 
 Antidepressants - Misc. Bupropion HCL Wellbutrin SR 
 Antidepressants - Misc. Bupropion HCL Wellbutrin XL 
  SSRIs Sertraline HCL Zoloft† 
Antidiabetics   Generic drugs:   
 Alpha-Glucosidase Inhibitors Acarbose 
  Sulfonylureas Glimepiride 
  Sulfonylureas Glipizide 
  Sulfonylureas Glipizide ER 
  Sulfonylureas Glipizide XL 
 
 
Sulfonylurea-Biguanide 
Combinations 
Glipizide-Metformin 
HCL 
  Sulfonylureas Glyburide 
  Sulfonylureas Glyburide Micronized 
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Table A.1 (Continued)   
Drug category Drug class Generic name Brand name 
 
Sulfonylurea-Biguanide 
Combinations 
Glyburide-MetFormin 
HCL 
  Biguanides Metformin HCl 
  Biguanides Metformin HCl ER  
  Meglitinide Analogues Nateglinide 
  Sulfonylureas Tolazamide 
  
 
Brand drugs: 
 
 
Thiazolidinedione-Biguanide 
Combinations 
Pioglitazone 
HCL/Metformin HCL Actoplus Met† 
 Thiazolidinediones Pioglitazone HCL Actos† 
 Sulfonylureas Glimepiride Amaryl 
 
Thiazolidinedione-Biguanide 
Combinations 
Rosiglitazone/Metformin 
HCL Avandamet† 
 
Sulfonylurea-Thiazolidinedione 
Combinations Rosiglitazone/Glimepiride Avandaryl† 
 Thiazolidinediones Rosiglitazone Maleate Avandia 
 Sulfonylureas Chlorpropamide Chlorpropamide 
 Sulfonylureas Glyburide Diabeta 
 
Sulfonylurea-Thiazolidinedione 
Combinations Pioglitazone/Glimepiride Duetact 
 Biguanides Metformin HCL Fortamet 
 Biguanides Metformin HCL Glucophage XR 
 Biguanides Metformin HCL Glucophage† 
 Sulfonylureas Glipizide Glucotrol 
 Sulfonylureas Glipizide Glucotrol XL 
 
Sulfonylurea-Biguanide 
Combinations 
Glyburide/Metformin 
HCL Glucovance† 
 Biguanides Metformin HCL Glumetza 
 Sulfonylureas Glyburide Glynase† 
 Alpha-Glucosidase Inhibitors Miglitol Glyset 
 
Dipeptidyl Peptidase-4 
Inhibitor-Biguanide 
Combinations 
Sitagliptin 
Phosphate/Metformin 
HCL 
Janumet† 
 
Dipeptidyl Peptidase-4 (DPP-4) 
Inhibitors Sitagliptin Phosphate Januvia† 
 
Sulfonylurea-Biguanide 
Combinations Glipizide/Metformin HCL Metaglip 
 
Dipeptidyl Peptidase-4 (DPP-4) 
Inhibitors Saxagliptin HCL Onglyza† 
 
Meglitinide-Biguanide 
Combinations 
Repaglinide/Metformin 
HCL Prandimet 
 Meglitinide Analogues Repaglinide Prandin† 
 Alpha-Glucosidase Inhibitors Acarbose Precose 
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Table A.1 (Continued)   
Drug category Drug class Generic name Brand name 
 Biguanides Metformin HCL Riomet 
 Meglitinide Analogues Nateglinide Starlix 
 Antidiabetic - Amylin Analogs Pramlintide Acetate Symlinpen† 
  Sulfonylureas Tolbutamide Tolbutamide 
Statins   Generic drugs:   
 
HMG CoA Reductase 
Inhibitors Lovastatin 
 
 
HMG CoA Reductase 
Inhibitors Pravastatin Sodium 
 
 
HMG CoA Reductase 
Inhibitors Simvastatin 
  
 
Brand drugs: 
 
 
HMG CoA Reductase Inhibitor 
Combinations Niacin/Lovastatin Advicor 
 
HMG CoA Reductase 
Inhibitors Lovastatin Altoprev 
 
Calcium Channel Blocker & 
HMG CoA Reductase Inhibit 
Comb 
Amlodipine/Atorvast 
Calcium Caduet† 
 
HMG CoA Reductase 
Inhibitors Rosuvastatin Calcium Crestor† 
 
HMG CoA Reductase 
Inhibitors Fluvastatin Sodium Lescol 
 
HMG CoA Reductase 
Inhibitors Fluvastatin Sodium Lescol XL 
 
HMG CoA Reductase 
Inhibitors Atorvastatin Calcium Lipitor† 
 
HMG CoA Reductase 
Inhibitors Lovastatin Mevacor 
 
HMG CoA Reductase 
Inhibitors Pravastatin Sodium Pravachol† 
 
HMG CoA Reductase Inhibitor 
Combinations Niacin/Simvastatin Simcor† 
 
Intest Cholest Absorp Inhib-
HMG CoA Reductase Inhib 
Comb 
Ezetimibe/Simvastatin Vytorin† 
  HMG CoA Reductase Inhibitors Simvastatin Zocor 
* Drug name, category, and brand/generic status designation were based on the Medi-Span® database. 
† Drugs with any prior authorization requirement. 
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Table A.2: Prediction of generic use for all hypothetical plans* 
 
Benefit 
design 
scenario 
Cost-sharing for a 
generic drug ($) 
Cost-sharing 
difference ($) 
Prior authorization Step therapy Predicted 
generic use 
  
Antidepressants 
  1 7 26 N N 75.3% 
2 7 26 N Y 76.6% 
3 7 26 Y N 79.7% 
4 7 26 Y Y 80.8% 
5 7 33 N N 77.1% 
6 7 33 N Y 78.4% 
7 7 33 Y N 81.3% 
8 7 33 Y Y 82.4% 
9 5 26 N N 76.5% 
10 5 26 N Y 77.8% 
11 5 26 Y N 80.8% 
12 5 26 Y Y 81.9% 
13 5 33 N N 78.3% 
14 5 33 N Y 79.5% 
15 5 33 Y N 82.3% 
16 5 33 Y Y 83.3% 
  
Antidiabetics 
  1 7 26 N N 79.0% 
2 7 26 N Y 79.6% 
3 7 26 Y N 81.1% 
4 7 26 Y Y 81.7% 
5 7 33 N N 80.4% 
6 7 33 N Y 81.0% 
7 7 33 Y N 82.4% 
8 7 33 Y Y 83.0% 
9 4 26 N N 80.4% 
10 4 26 N Y 81.0% 
11 4 26 Y N 82.5% 
12 4 26 Y Y 83.0% 
13 4 33 N N 81.8% 
14 4 33 N Y 82.3% 
15 4 33 Y N 83.7% 
16 4 33 Y Y 84.2% 
  
Statins 
   1 7 25 N N 55.9% 
2 7 25 N Y 58.9% 
3 7 25 Y N 58.8% 
4 7 25 Y Y 61.7% 
5 7 32 N N 58.9% 
6 7 32 N Y 61.8% 
7 7 32 Y N 61.7% 
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Table A.2 (Continued) 
    
Benefit 
design 
scenario 
Cost-sharing for a 
generic drug ($) 
Cost-sharing 
difference ($) 
Prior authorization Step therapy Predicted 
generic use 
8 7 32 Y Y 64.6% 
9 5 25 N N 59.0% 
10 5 25 N Y 61.9% 
11 5 25 Y N 61.8% 
12 5 25 Y Y 64.6% 
13 5 32 N N 61.9% 
14 5 32 N Y 64.8% 
15 5 32 Y N 64.6% 
16 5 32 Y Y 67.4% 
*For each drug category, we calculated marginal effects of plan features on the use of generic 
drugs for 16 scenarios. We chose different combinations of the 25th and 75th percentiles of the 
cost-sharing for generic drugs, the 25th and 75th percentiles of the cost-sharing difference between 
brand and generic drugs, and whether or not prior authorization or step therapy was used. All 
covariates were adjusted for the predictions. 
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APPENDIX B: TABLES FOR CHAPTER 2 
 
 
 
 
 
Figure B.1: Change of concentration (HHI) by number of patients 
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 Figure B.2: Flow chart for the study sample 
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Figure B.3: Most preferred antipsychotics by psychiatrists 
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Table B.1: Sensitivity analysis results for number of ingredients 
 
Variables 
Coefficients (standard errors) 
Equal weights 
1:1 
Weighting 
ratio 10:1 
Weighting 
ratio 2:1 
Characteristics of provider’s treated patients    
 Share of female patients (%) -0.01 (0.01) -0.01 (0.01) -0.01 (0.01) 
 Share of SSI-eligible patients (%) 0.02 (0.01)** 0.02 (0.01)** 0.02 (0.01)** 
 Share of non-Hispanic whites (%) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 
 Share of patients <18 years old (%) -0.03 (0.00)*** -0.03 (0.00)*** -0.03 (0.00)*** 
 Share of patients ≥50 years old (%) 0.00 (0.01) 0.00 (0.01) 0.00 (0.01) 
 Share of patients with serious mental illnesses (%) 0.02 (0.01)*** 0.02 (0.01)*** 0.02 (0.01)*** 
 
Share of patients with 2+ non-mental comorbidities 
(%) 0.01 (0.01) 0.01 (0.01) 0.01 (0.01) 
 Share of patients enrolled in fee-for-services (%) 0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 
Physician characteristics    
 Physician sex (ref = male)    
  Female -0.29 (0.18)* -0.29 (0.18)* -0.29 (0.18)* 
 Physician age (ref = <40)    
  40–49 0.19 (0.25) 0.17 (0.25) 0.18 (0.25) 
  50–59 -0.03 (0.25) -0.06 (0.25) -0.04 (0.25) 
  ≥60 0.27 (0.27) 0.24 (0.27) 0.26 (0.27) 
 Attended medical school (ref = ranked ≥21)    
  US top 20 -0.27 (0.30) -0.26 (0.3) -0.26 (0.30) 
  Foreign schools 0.12 (0.17) 0.11 (0.17) 0.11 (0.17) 
 Total number of antipsychotic prescriptions 0.00 (0.00)*** 0.00 (0.00)*** 0.00 (0.00)*** 
 Number of other antipsychotic prescribers in the same organizations (ref = 0)  
  1–9 0.17 (0.33) 0.18 (0.33) 0.18 (0.33) 
  ≥10 0.30 (0.34) 0.35 (0.34) 0.32 (0.34) 
 Practice location (ref = otherwise)    
  Urban only -0.24 (0.27) -0.24 (0.27) -0.24 (0.27) 
Organizational setting    
 Organization specialty (ref = otherwise)    
  
Any affiliation with a behavioral health 
organization 0.79 (0.45)* 0.80 (0.45)* 0.79 (0.45)* 
 Organizational affiliation type (ref = outpatient only)   
  Inpatient only 0.35 (0.48) 0.36 (0.49) 0.36 (0.49) 
  Both inpatient and outpatient 0.12 (0.28) 0.05 (0.28) 0.09 (0.28) 
 Organization size  0.00 (0.00)* 0.00 (0.00) 0.00 (0.00)* 
Intercept 5.13 (0.95)*** 5.07 (0.96)*** 5.11 (0.96)*** 
*p<.1, **p<.05, ***p<.01. 
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Table B.2: Sensitivity analysis results for share of most preferred ingredient 
 
Variables 
Coefficients (standard errors) 
Equal weights 
1:1 
Weighting 
ratio 10:1 
Weighting 
ratio 2:1 
Characteristics of provider’s treated patients    
 Share of female patients (%) 0.02 (0.03) 0.02 (0.00) 0.02 (0.03) 
 Share of SSI-eligible patients (%) -0.16 (0.03)*** -0.16 (0.00)*** -0.16 (0.03)*** 
 Share of non-Hispanic whites (%) -0.03 (0.02)* -0.03 (0.00)** -0.03 (0.02)* 
 Share of patients <18 yrs (%) 0.07 (0.02)*** 0.07 (0.00)*** 0.07 (0.02)*** 
 Share of patients ≥50 yrs (%) -0.08 (0.04)** -0.08 (0.00)** -0.08 (0.04)** 
 
Share of patients with serious mental illnesses 
(%) -0.11 (0.03)*** -0.11 (0.00)*** -0.11 (0.03)*** 
 
Share of patients with 2+ non-mental 
comorbidities (%) 0.06 (0.04) 0.06 (0.00) 0.06 (0.04) 
 Share of patients enrolled in fee-for-services (%) 0.02 (0.01) 0.02 (0.00) 0.02 (0.01) 
Physician characteristics    
 Physician sex (ref = male)    
  Female 1.22 (0.80) 1.23 (1.00) 1.22 (0.80) 
 Physician age (ref = <40)    
  40–49 1.06 (1.14) 1.05 (1.00) 1.05 (1.14) 
  50–59 1.26 (1.13) 1.24 (1.00) 1.24 (1.13) 
  ≥60 1.92 (1.22) 1.92 (1.00) 1.92 (1.22) 
 Attended medical school (ref = ranked ≥21)    
  US top 20 1.89 (1.33) 1.9 (1.00) 1.90 (1.33) 
  Foreign schools 1.40 (0.76)* 1.41 (1.00)* 1.40 (0.76)* 
 Total number of antipsychotic prescriptions 0.00 (0.00)*** 0.00 (0.00)*** 0.00 (0.00)*** 
 Number of other antipsychotic prescribers in the same organizations (ref = 0)  
  1–9 0.07 (1.46) 0.06 (1.00) 0.06 (1.46) 
  ≥10 1.27 (1.47) 1.26 (1.00) 1.28 (1.47) 
 Practice location (ref = otherwise)    
  Urban only 0.78 (1.20) 0.79 (1.00) 0.78 (1.20) 
Organizational setting    
 Organization specialty (ref = otherwise)    
  
Any affiliation with a behavioral health 
organization 1.46 (1.95) 1.42 (2.00) 1.44 (1.95) 
 Organizational affiliation type (ref = outpatient only)   
  Inpatient only 2.77 (2.08) 2.74 (2.00) 2.76 (2.08) 
  Both inpatient and outpatient 1.48 (1.23) 1.50 (1.00) 1.49 (1.22) 
 Organization size  0.00 (0.00) 0.00 (0.00) 0.00 (0.00) 
Intercept 50.75 (4.23)*** 50.85 (4.00)*** 50.79 (4.23)*** 
*p<.1, **p<.05, ***p<.01.
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Table B.3: Sensitivity analysis results for HHI of ingredients 
 
Variables 
Coefficients (standard errors) 
Equal weights 
1:1 
Weighting ratio 
10:1 
Weighting ratio 
2:1 
Characteristics of provider’s treated patients    
 Share of female patients (%) 3.80 (2.24)* 3.80 (2.24)* 3.80 (2.24)* 
 Share of SSI-eligible patients (%) -13.14 (2.32)*** -13.14 (2.32)*** -13.14 (2.32)*** 
 Share of non-Hispanic whites (%) -2.03 (1.27) -2.12 (1.26)* -2.07 (1.27)* 
 Share of patients <18 yrs (%) 8.04 (1.61)*** 8.00 (1.61)*** 8.03 (1.61)*** 
 Share of patients ≥50 yrs (%) -5.63 (3.03)* -5.59 (3.03)* -5.60 (3.03)* 
 Share of patients with serious mental illnesses (%) -9.00 (2.26)*** -9.00 (2.25)*** -9.00 (2.26)*** 
 
Share of patients with 2+ non-mental 
comorbidities (%) 3.77 (3.07) 3.69 (3.08) 3.74 (3.08) 
 Share of patients enrolled in fee-for-services (%) 1.73 (1.09) 1.80 (1.09)* 1.77 (1.09) 
Physician characteristics    
 Physician sex (ref = male)    
  Female 96.15 (58.85)* 97.88 (58.88)* 96.77 (58.87)* 
 Physician age (ref = <40)    
  40–49 66.89 (83.84) 61.14 (83.81) 64.86 (83.87) 
  50–59 81.43 (82.90) 75.34 (82.84) 78.99 (82.91) 
  ≥60 107.42 (89.67) 102.16 (89.71) 105.51 (89.73) 
 Attended medical school (ref = ranked ≥21)    
  US top 20 127.76 (97.91) 132.42 (97.91) 129.44 (97.92) 
  Foreign schools 62.04 (55.90) 62.31 (56.00) 62.18 (55.94) 
 Total number of antipsychotic prescriptions -0.22 (0.03)*** -0.22 (0.03)*** -0.22 (0.03)*** 
 Number of other antipsychotic prescribers in the same organizations (ref = 0)  
  1–9 -65.34 (107.82) -66.78 (107.66) -65.97 (107.79) 
  ≥10 -36.41 (110.21) -32.50 (109.72) -34.82 (110.08) 
 Practice location (ref = otherwise)    
  Urban only 39.62 (88.73) 41.70 (88.82) 40.30 (88.77) 
Organizational setting    
 Organization specialty (ref = otherwise)    
  
Any affiliation with a behavioral health 
organization 52.18 (145.26) 45.43 (145.65) 49.71 (145.51) 
 Organizational affiliation type (ref = outpatient only)   
  Inpatient only 135.49 (155.87) 136.15 (155.77) 135.49 (155.94) 
  Both inpatient and outpatient 95.71 (91.53) 102.52 (90.58) 98.63 (91.14) 
 Organization size  0.07 (0.07) 0.04 (0.07) 0.06 (0.07) 
Intercept 3737.34 (312.77)*** 
3754.72 
(312.65)*** 
3744.86 
(312.81)*** 
*p<.1, **p<.05, ***p<.01. 
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APPENDIX C: TABLES FOR CHAPTER 3 
 
 
 
Table C.1: Provider clozapine and polypharmacy practices by schizophrenia-related 
hospitalization among patient population (quartiles), 2010-2012 
 
Share of patients with 
schizophrenia-related 
hospitalization (%) 
Any 
clozapine 
prescribing 
(%) 
Any 
polypharmacy 
prescribing 
(%) 
Share of 
patients w/ 
clozapine use 
(%)* 
Share of patients 
w/ polypharmacy 
use (%)* 
Year 2010         
 
1st quartile (0.0-24.7%) 46.20 60.76 4.98 (7.13) 6.50 (7.79) 
 
2nd quartile (25.0-36.0%) 60.00 66.67 7.06 (11.94) 7.59 (8.26) 
 
3rd quartile (36.1-53.3%) 58.39 68.94 6.53 (9.01) 7.20 (7.91) 
 
4th quartile (53.8-100.0%) 59.63 29.19 4.89 (7.40) 2.08 (3.92) 
Year 2011          
 
1st quartile (0.0-25.6%) 57.59 76.58 7.28 (10.14) 9.30 (8.97) 
 
2nd quartile (25.8-38.5%) 67.50 75.63 8.69 (11.85) 9.80 (9.34) 
 
3rd quartile (38.9-61.1%) 58.60 61.15 6.67 (11.18) 6.72 (8.29) 
 
4th quartile (61.4-100.0%) 56.05 24.2 5.07 (7.56) 1.75 (4.04) 
Year 2012          
 
1st quartile (0.0-25.0%) 61.21 73.33 9.32 (12.29) 9.45 (9.28) 
 
2nd quartile (25.5-37.3%) 63.06 74.52 6.84 (9.48) 9.18 (8.33) 
 
3rd quartile (37.5-60.0%) 59.64 63.25 6.40 (9.50) 7.73 (9.00) 
  4th quartile (60.7-100.0%) 56.79 20.37 4.82 (6.10) 1.70 (4.58) 
*Figures within parentheses are means and SDs. 
 90 
Table C.2: GEE regression results for subset cohort (antipsychotic prescribers with 3 
years' data): predictors of clozapine and antipsychotic polypharmacy 
prescribing 
 
Variables 
Odds Ratios (robust standard error) 
Clozapine 
prescribing 
Antipsychotic 
polypharmacy 
prescribing 
Characteristics of provider's treated patients   
 Demographic information   
  Share of female patients (%) 1.00  (0.00) 1.00  (0.00) 
  Share of SSI-eligible patients (%) 1.02 (0.00)*** 1.01 (0.00)*** 
  Share of Hispanic patients (%) 0.98 (0.00)*** 0.99 (0.00)*** 
  Share of non-Hispanic black patients (%) 0.99 (0.00)*** 1.00  (0.00) 
  Mean age of patients 0.98 (0.01) 0.99 (0.01) 
 Health status and hospitalization   
  Share of patients with affective disorders (%) 0.99 (0.00)*** 1.00  (0.00) 
  Share of patients with anxiety disorders (%) 0.99 (0.00)* 0.99 (0.00)* 
  Share of patients with other psychiatric disorders (%) 1.00 (0.01) 1.01 (0.01) 
  Share of patients with substance use disorders (%) 0.99 (0.00)*** 1.00 (0.00) 
  Share of patients with brain impairment comorbidity (%) 1.00 (0.00) 1.01 (0.00)** 
  Mean number of non-mental health comorbidities 1.25 (0.10)*** 1.01 (0.07) 
  Share of patients with schizophrenia-related hospitalization (%) 1.01 (0.00)** 0.99 (0.00)*** 
 Health insurance   
  Number of plans for treated patients 1.05 (0.03)** 0.94 (0.02)*** 
      The predominant plan among patient population (ref = FFS)   
   MCO plan A 0.91 (0.18) 1.55 (0.18)*** 
   MCO plan B 0.93 (0.22) 1.67 (0.59) 
   MCO plan C 1.03 (0.17) 1.36 (0.16)*** 
   MCO plan E 0.90 (0.20) 0.59 (0.12)*** 
   MCO plan F 2.48 (1.54) 2.70 (1.10)** 
   MCO plan G 1.15 (0.23) 0.73 (0.11)** 
   MCO plan H 1.01 (0.21) 1.49 (0.23)*** 
   MCO plan I 1.51 (0.48) 1.38 (0.26)* 
   MCO plan J (combined)† 1.51 (0.36)* 0.69 (0.32) 
Provider characteristics   
 High prescription volume (ref = low prescription volume) 1.50 (0.15)*** 2.29 (0.20)*** 
 Female  (ref = male) 1.12 (0.17) 1.02 (0.09) 
 Specialty (ref = psychiatrist)   
  Primary care provider 0.40 (0.09)*** 0.84 (0.27) 
  Other 0.77 (0.20) 1.01 (0.19) 
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Table C.2 (Continued)   
Variables 
Odds Ratios (robust standard error) 
Clozapine 
prescribing 
Antipsychotic 
polypharmacy 
prescribing 
 Practice in urban only (ref=otherwise) 0.98 (0.25) 0.99 (0.18) 
Year (ref = 2010)   
 2011 0.97 (0.05) 1.20 (0.06)*** 
 2012 0.95 (0.07) 1.18 (0.07)*** 
Intercept 0.04 (0.03)*** 0.05 (0.03)*** 
N obs 1,278 1,278 
N groups  426 426 
*p<.1, **p<.05, ***p<.01. 
†MCO plan J combined plans with only 1-3 observations in a year.
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Table C.3: GEE regression results for psychiatrists: predictors of share of patients with 
clozapine use and share of patients with antipsychotic polypharmacy 
prescribing 
 
Variables 
  
  
Odds Ratios (robust standard error) 
Clozapine 
prescribing 
Antipsychotic 
polypharmacy 
prescribing 
Characteristics of provider's treated patients   
 Demographic information   
  Share of female patients (%) 1.00 (0.00) 1.00 (0.00) 
  Share of SSI-eligible patients (%) 1.02 (0.00)*** 1.02 (0.00)*** 
  Share of Hispanic patients (%) 0.98 (0.00)*** 0.99 (0.00)*** 
  Share of non-Hispanic black patients (%) 0.99 (0.00)*** 1.00 (0.00) 
  Mean age of patients 0.99 (0.01) 0.98 (0.01)** 
 Health status and utilization   
  Share of patients with affective disorders (%) 0.99 (0.00)*** 1.00 (0.00) 
  Share of patients with anxiety disorders (%) 0.99 (0.00)* 0.99 (0.00)** 
  Share of patients with other psychiatric disorders (%) 1.00 (0.00) 1.00 (0.01) 
  Share of patients with substance use disorders (%) 0.99 (0.00)*** 0.99 (0.00)*** 
  Share of patients with brain impairment comorbidity (%) 1.00 (0.00) 1.00 (0.00) 
  Mean number of non-mental health comorbidities 1.12 (0.08) 1.12 (0.07)* 
  Share of patients with schizophrenia-related hospitalization (%) 1.01 (0.00)*** 0.99 (0.00)*** 
 Health insurance   
  Number of plans for treated patients 1.04 (0.03) 0.96 (0.02)* 
  The predominant plan among patient population (ref = FFS)  
   MCO plan A 0.95 (0.16) 1.61 (0.18)*** 
   MCO plan B 0.76 (0.18) 1.63 (0.63) 
   MCO plan C 1.14 (0.18) 1.54 (0.17)*** 
   MCO plan D 2.68 (0.91)*** 0.64 (0.25) 
   MCO plan E 0.85 (0.16) 0.76 (0.13) 
   MCO plan G 1.17 (0.19) 0.83 (0.12) 
   MCO plan H 1.17 (0.21) 1.54 (0.21)*** 
   MCO plan I 1.67 (0.45)* 1.35 (0.25) 
   MCO plan J (combined)† 1.30 (0.31) 0.81 (0.34) 
Provider characteristics   
 High prescription volume (ref = low prescription volume) 1.40 (0.12)*** 2.64 (0.22)*** 
 Female  (ref = male) 1.15 (0.13) 0.94 (0.08) 
 Practice in urban only (ref=otherwise) 1.04 (0.22) 1.09 (0.15) 
Year (ref = 2010)   
 2011 1.00 (0.05) 1.14 (0.06)** 
 2012 0.96 (0.07) 1.08 (0.07) 
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Table C.3 (Continued)   
Variables 
Odds Ratios (robust standard error) 
Clozapine 
prescribing 
Antipsychotic 
polypharmacy 
prescribing 
Intercept 0.04 (0.02)*** 0.04 (0.02)*** 
N obs 1,584 1,584 
N groups  695 695 
*p<.1, **p<.05, ***p<.01. 
†MCO plan J combined plans with only 1-3 observations in a year.  
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Table C.4: GEE regression results controlling for practice region: predictors of share of 
patients with clozapine use and share of patients with antipsychotic 
polypharmacy prescribing 
 
Variables 
Odds Ratios (robust standard error) 
Clozapine 
prescribing 
Antipsychotic 
polypharmacy 
prescribing 
Characteristics of provider's treated patients   
 Demographic information   
  Share of female patients (%) 1.00 (0.00) 1.00 (0.00) 
  Share of SSI-eligible patients (%) 1.02 (0.00)*** 1.02 (0.00)*** 
  Share of Hispanic patients (%) 0.98 (0.00)*** 0.99 (0.00)*** 
  Share of non-Hispanic black patients (%) 0.99 (0.00)*** 1.00 (0.00)* 
  Mean age of patients 0.98 (0.01)** 0.99 (0.01) 
 Health status and utilization   
  Share of patients with affective disorders (%) 0.99 (0.00)*** 1.00 (0.00) 
  Share of patients with anxiety disorders (%) 0.99 (0.00)* 0.99 (0.00)*** 
  Share of patients with other psychiatric disorders (%) 1.00 (0.01) 1.01 (0.01) 
  Share of patients with substance use disorders (%) 0.99 (0.00)*** 0.99 (0.00)*** 
  Share of patients with brain impairment comorbidity (%) 1.00 (0.00) 1.01 (0.00)** 
  Mean number of non-mental health comorbidities 1.15 (0.07)** 1.12 (0.06)* 
  Share of patients with schizophrenia-related hospitalization (%) 1.01 (0.00)*** 0.99 (0.00)*** 
 Health insurance   
  Number of plans for treated patients 1.04 (0.02)* 0.96 (0.02)** 
  The predominant plan among patient population (ref = FFS) 
   MCO plan A 0.81 (0.14) 1.46 (0.19)*** 
   MCO plan B 0.76 (0.16) 1.39 (0.45) 
   MCO plan C 1.00 (0.15) 1.29 (0.15)** 
   MCO plan D 2.67 (0.95)*** 1.26 (0.57) 
   MCO plan E 1.10 (0.23) 0.88 (0.15) 
   MCO plan F 1.76 (0.64) 1.33 (0.40) 
   MCO plan G 1.35 (0.24)* 0.95 (0.13) 
   MCO plan H 1.24 (0.22) 1.56 (0.20)*** 
   MCO plan I 1.72 (0.45)** 1.47 (0.24)** 
   MCO plan J (combined)† 1.29 (0.30) 0.80 (0.32) 
Provider characteristics   
 High prescription volume (ref = low prescription volume) 1.43 (0.11)*** 2.65 (0.19)*** 
 Female  (ref = male) 1.08 (0.12) 1.01 (0.07) 
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Table C.4 (Continued)   
Variables 
Odds Ratios (robust standard error) 
Clozapine 
prescribing 
Antipsychotic 
polypharmacy 
prescribing 
 Specialty (ref = psychiatrist)   
  Primary care provider 0.54 (0.12)*** 1.11 (0.20) 
  Other 1.00 (0.17) 0.83 (0.11) 
 Practice county (ref = Philadelphia)   
  Allegheny 1.63 (0.31)** 1.37 (0.21)** 
  Other 1.14 (0.16) 1.24 (0.14)* 
 Practice in urban only (ref=otherwise) 0.98 (0.19) 0.95 (0.13) 
Year (ref = 2010)   
 2011 1.02 (0.05) 1.15 (0.06)*** 
 2012 0.98 (0.07) 1.12 (0.06)** 
Intercept 0.05 (0.03)*** 0.03 (0.01)*** 
N obs 1,927 1,927 
N groups 892 892 
*p<.1, **p<.05, ***p<.01. 
†MCO plan J combined plans with only 1-3 observations in a year. 
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